Radiolabeled MET-binding protein for immuno-PET imaging
Radiolabeled anti-MET antibody and MET x MET bispecific antibody conjugates for immuno-PET imaging address the need for detecting MET-expressing tumors, enhancing targeted therapy by providing accurate visualization and quantification of MET expression.
Patent Information
- Application Number
- KR1020227009999
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-16
- Filing Date
- 2020-09-15
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2040-09-15
AI Technical Summary
There is a need for a diagnostic tool that enables the detection of MET-expressing tumors for targeted therapy, as MET overexpression or mutations are associated with various carcinomas and resistance to targeted therapies.
Development of radiolabeled anti-MET antibody and MET x MET bispecific antibody conjugates for immuno-PET imaging, which include a chelating moiety and a positron emitter, allowing visualization of MET expression in tissues.
Enables accurate visualization and quantification of MET expression in tissues, facilitating the identification of tumors suitable for anti-MET therapy and monitoring treatment efficacy.
Smart Images

Figure 112022032234899-PCT00024_ABST
Abstract
Description
Technology Field
[0001] The present disclosure relates to a radiolabeled MET-binding protein and its use in immuno-PET imaging.
[0002] Sequence list
[0003] An official copy of the sequence list is a sequence list in ASCII format of approximately 136 KB in size, created on September 15, 2020, with the filename "10649WO01_SEQ_LIST_ST25.txt", and is submitted electronically via EFS-Web together with this specification. The sequence list contained in this document in ASCII format is part of this specification and the whole is incorporated herein by reference. Background Technology
[0004] Hepatocyte growth factor (HGF) (also known as scattering factor [SF]) is a heterodimeric paracrine growth factor that exerts its activity by interacting with the HGF receptor (HGFR). HGFR is a product of the c-Met oncogene and is also known as MET. MET is a receptor tyrosine kinase consisting of a transmembrane beta chain linked to an extracellular alpha chain via a disulfide bridge. The binding of HGF to MET activates the kinase catalytic activity of MET, phosphorylating Tyr 1234 and Tyr 1235 of the beta chain and subsequently activating downstream signaling pathways.
[0005] MET and / or HGF overexpression, activation, or amplification has been found to be associated with non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colorectal, and renal carcinomas (Sierra and Tsao, Ther. Adv. Med. Oncol., 3(1 Suppl): S21-S35, 2011). MET amplification is considered a major oncogenic driver in NSCLC and esophageal gastric cancer. Additionally, mutations resulting in exon 14 deletion of MET have been described as oncogenic drivers in a subset of NSCLC. Tumor cell lines with MET gene amplification are highly dependent on MET for growth and survival. Preclinical data suggest MET signaling in resistance to targeted therapy in a number of tumor types, such as NSCLC, colorectal cancer, and high-NSCC.
[0006] Immuno-positron emission tomography (PET) is a diagnostic imaging tool that uses monoclonal antibodies labeled with a positron emitter, combining the targeting characteristics of the antibodies with the sensitivity of a positron emission tomography camera. for example, The Oncologist , 12: 1379 (2007); Journal of Nuclear Medicine See , 52(8): 1171 (2011). Immuno-PET enables the visualization and quantification of antigen and antibody accumulation in vivo and can therefore be used as an important tool for diagnosis and complementary therapy. For example, immuno-PET can help in the screening of potential candidates for specific therapies as well as the monitoring of treatment.
[0007] Both preclinical and recent clinical results demonstrate that tumors harboring MET gene mutations respond to MET inhibitors, proving that MET is a carcinogen. As such, especially There is a need for a diagnostic tool for anti-MET and / or anti-MET therapy, which includes a diagnostic tool that enables the detection of candidate substances suitable for the aforementioned treatment.
[0008] The present disclosure includes a radiolabeled anti-MET antibody conjugate and a MET x MET bispecific antibody conjugate for use in immuno-PET imaging.
[0009] In one embodiment, the conjugate comprises an anti-MET antibody, a MET x MET bispecific antibody conjugate, or an antigen-binding fragment thereof, a chelating moiety, and a positron emitter.
[0010] In addition, a process for synthesizing the aforementioned conjugate and a synthetic intermediate useful therefor are provided herein.
[0011] A method for imaging tissues expressing MET is also provided herein, comprising the steps of: administering a radiolabeled anti-MET antibody conjugate or a MET x MET bispecific antibody conjugate described herein to a tissue; and visualizing MET expression by positron emission tomography (PET) imaging.
[0012] A method for detecting MET in tissue is also provided herein, comprising the steps of: administering the radiolabeled anti-MET antibody conjugate or MET x MET bispecific antibody conjugate described herein to tissue; and visualizing MET expression by PET imaging. In one embodiment, the tissue is present in a human subject. In a specific embodiment, the subject is a non-human mammal. In a specific embodiment, the subject has a disease or disorder such as cancer.
[0013] A method for determining the presence of MET-expressing cells in a subject is also provided herein. The method comprises the steps of administering the radiolabeled anti-MET antibody conjugate or MET x MET bispecific antibody conjugate described herein to a subject and visualizing MET expression by PET imaging.
[0014] Additionally, a method is provided herein for identifying a subject having a solid tumor suitable for anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway, e.g., an anti-MET antibody, a MET x MET bispecific antibody, or an antibody-drug conjugate (ADC) thereof. The method comprises the steps of administering the radiolabeled antibody conjugate described herein to the subject and visualizing the administered radiolabeled antibody conjugate in the tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present within the tumor, the subject is identified as suitable for anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway.
[0015] Additionally, a method for treating a tumor within a subject is provided herein, the method comprising the steps of: determining whether a solid tumor is MET-positive; and administering an anti-tumor therapy to a subject requiring such therapy. In certain embodiments, the anti-tumor therapy comprises an anti-MET antibody or a MET x MET bispecific antibody. In certain embodiments, the radiolabeled antibody conjugate described herein is administered to a subject, and the localization of the radiolabeled antibody conjugate is visualized via positron emission tomography (PET) imaging to determine whether the tumor is MET-positive.
[0016] Additionally, a method for monitoring the efficacy of anti-tumor therapy in a subject being treated with anti-tumor therapy is provided herein, the method comprising the steps of: administering the radiolabeled conjugate described herein to a subject; imaging the localization of the administered radiolabeled conjugate within the tumor by PET imaging; and determining tumor growth, wherein tumor regression and the efficacy of anti-tumor therapy are indicated by a decrease in the uptake of the conjugate or radiolabeled signal relative to baseline. In certain embodiments, the anti-tumor therapy comprises an inhibitor of the HGF / MET signaling pathway (e.g., an anti-MET antibody or a MET x MET bispecific antibody, or an ADC of one of these).
[0017] Additionally, a method for predicting a subject's response to an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway is provided herein, the method comprising the step of determining whether a tumor is MET-positive, wherein if the tumor is MET-positive, this indicates a positive response of the subject to an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway. In a specific embodiment, the tumor is determined to be positive by administering the radiolabeled antibody conjugate of the present disclosure and localizing the radiolabeled antibody conjugate within the tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present within the tumor, the tumor indicates that it is MET-positive.
[0018] A method for diagnosing and treating a subject having a tumor is provided herein, the method comprising the steps of: administering a radiolabeled conjugate described herein to a subject, imaging the localization of the radiolabeled antibody conjugate via PET imaging to determine whether the tumor is MET-positive; diagnosing the subject as having a MET-positive tumor; and administering an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway to the subject.
[0019] A method for diagnosing a subject having a MET-expressing tumor is provided herein, comprising the steps of: administering a radiolabeled anti-MET antibody conjugate or a MET x MET bispecific antibody conjugate described herein to a subject; visualizing MET expression by PET imaging; and diagnosing the subject as a MET-expressing tumor when MET expression is visualized by PET imaging. Brief explanation of the drawing
[0020] Fig. 1 Figure 1 shows the SE-HPLC chromatogram of 5 µg of DFO-MET x MET immunoconjugate injected onto a Superdex 200 Increase column using UV 280 nm absorbance detection. Monomers (99.6%) and high molecular weight (HMW) species (0.4%) are indicated. Fig. 2 Figure [Image] shows an SDS-PAGE image of the DFO-MET x MET immunoconjugate. The gel demonstrates that antibody integrity remained unchanged after DFO conjugation. Lanes are labeled as follows: 1) Standard ladder (BioRad, Catalog #: 161-0374), 2) Non-reduced bispecific antibody, 3) Non-reduced DFO-Ab immunoconjugate, 4) Blank, 5) Reduced bispecific antibody, 6) Non-reduced DFO-Ab immunoconjugate. Approximately 2 µg of protein was loaded into each well. Note that the non-reduced antibody generally exhibits lower electrophoretic motility than expected compared to the ladder for the standard SDS-PAGE setup. Fig. 3 Figure 1 shows a representative SE-HPLC radiochromatogram using gamma emission detection of an injected 5 µg radioimmunoconjugate (DFO-MET x MET bispecific antibody). While the RCP exceeds 95%, the unintegrated 89 Zr accounts for less than 1% of total integrated activity. Fig. 4This shows the SE-HPLC UV absorption chromatogram of 5 µg of injected radioimmunoconjugate (DFO-MET x MET bispecific antibody). The dominant species (97.9%) and HMW (2.1%) species are indicated. The elution peak between 25 and 31 minutes is a phenomenon of the formulation buffer / mobile phase mixture and is not considered to be of protein origin. Fig. 5 PET / CT images of EBC-1 tumor xenografts in mice are shown. Mice were administered a radiolabeled MET x MET bispecific antibody conjugate, and over several days, a conjugate specifically localized to MET-expressing tumor xenografts was administered. Fig. 6 PET / CT images of NCI-H441 tumor xenografts in mice are shown. Mice were administered a radiolabeled MET x MET bispecific antibody conjugate, and over several days, a conjugate specifically localized to MET-expressing tumor xenografts was administered. Fig. 7 PET / CT images of NCI-H358 tumor xenografts in mice are shown. Mice were administered a radiolabeled MET x MET bispecific antibody conjugate, and over several days, a conjugate specifically localized to MET-expressing tumor xenografts was administered. Fig. 8a , Fig. 8b , Fig. 8c , Fig. 8d , Fig. 8e , and Fig. 8f is in SCID mice with tumor xenografts 89 We provide in vitro biodistribution data for Zr-DFO-MET x MET bispecific antibody conjugates. 0.1 mg / kg, 0.5 mg / kg, or 5.0 mg / kg of 0.1 mg / kg in mice 89A single IV administration of the Zr-DFO-MET x MET bispecific antibody conjugate was performed, and the subjects were sacrificed after 6 days. Blood collected via cardiac puncture and labeled tissue samples were weighed, and radioactivity was measured. The percentage of the injected dose per gram (%ID / g) for individual samples collected on day 6 was the injected substance ( 89 The dose-standard radioactivity and individual sample weights from the Zr-DFO-MET x MET bispecific antibody conjugate were calculated. Data were plotted as mean ± SD. Fig. 9 Is 89 This shows the correlation between the uptake of Zr-DFO-MET x MET bispecific antibodies and the levels of MET expression in tumor xenografts from three MET-expressing cell lines. Fig. 10a and Fig. 10b This represents antibody saturation binding data for three MET-expressing cell lines. Specific details for implementing the invention
[0021] I. Definition
[0022] Before describing the present invention, it should be understood that the invention is not limited to the specific methods and experimental conditions described, as such methods and conditions may vary. Furthermore, since the scope of the invention is limited only by the appended claims, it should be understood that the terms used herein are for the purpose of describing specific embodiments and are not intended to be limiting.
[0023] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the disclosed subject matter belongs. When used herein in relation to specific cited figures, the term “about” means that such values may differ from the cited values by less than 1%. For example, the expression “about 100” used herein includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0024] Any methods and materials similar or equivalent to those described herein may also be used for the practice or testing of the present invention, but preferred methods and materials are described below. All patents, applications, and non-patent publications mentioned herein are incorporated herein by reference in their entirety.
[0025] MET protein
[0026] Expressions such as "MET" and "c-Met" as used herein refer to (1) isoform "a" of unprocessed preproprotein, comprising and / or having an amino acid sequence as presented in SEQ ID NO. 145 or having and / or having an amino acid sequence as presented in NCBI Accession No. NM_001127500.2, (2) isoform "b" of unprocessed preproprotein, comprising and / or having an amino acid sequence as presented in SEQ ID NO. 146 or having and / or having an amino acid sequence as presented in NCBI Accession No. NM_000236.2, (3) isoform "c" of unprocessed preproprotein, comprising and / or having an amino acid sequence as presented in NCBI Accession No. 147 or having and / or having an amino acid sequence as presented in NCBI Accession No. NM_001311330.1, or (3) cytoplasm shared by all three isoforms Receptor tyrosine kinase present in the human cell membrane, comprising a mature protein containing an alpha subunit (SEQ No. 148) and a transmembrane beta subunit (SEQ No. 149, 150, or 151, respectively for isoforms a, b, and c). The expression “MET” includes both monomeric and multimeric MET molecules. As used herein, the expression “monomeric human MET” means a MET protein or a part thereof existing under normal conditions as a single MET molecule without a direct physical linkage to another MET molecule, with or without any multimeric domain. An exemplary monomeric MET molecule is the molecule referred herein as “hMET.mmh” comprising the amino acid sequence of SEQ No. 152 (see, for example, Example 3 of US-2018-0134794). As used herein, the expression “dimeric human MET” means a composition comprising two MET molecules connected to each other through a linker, covalent bond, non-covalent bond, or through a multimerization domain such as an antibody Fc domain.An exemplary dimeric MET molecule is the molecule referred herein as "hMET.mFc" comprising the amino acid sequence of SEQ ID NO. 153 (see, for example, Example 3 of US-2018-0134794).
[0027] All references to proteins, polypeptides, and protein fragments herein are intended to refer to the human versions of each protein, polypeptide, or protein fragment, provided they are of non-human origin and are explicitly stated otherwise. Accordingly, the term "MET" refers to human MET unless otherwise specified as being of non-human origin, e.g., "mouse MET," "monkey MET," etc.
[0028] As used herein, the term “cell surface-expressed MET” means one or more MET protein(s) or their extracellular domains expressed on the surface of a cell in vitro or in vivo such that at least a portion of the MET protein is exposed to the extracellular side of the cell membrane and can access the antigen-binding portion of an antibody. “Cell surface-expressed MET” may include or consist of MET proteins expressed on the surface of a cell that normally expresses MET proteins. Alternatively, “cell surface-expressed MET” may include or consist of MET proteins expressed on the surface of a cell that normally does not express human MET on its surface but has been artificially engineered to express MET on its surface.
[0029] Other definitions
[0030] As used herein, the term “antibody” is intended to refer to an immunoglobulin molecule comprising four polypeptide chains, two heavy chains (H) and two light chains (L) interconnected by disulfide bonds (i.e., a “full antibody molecule”), as well as a polymer thereof (e.g., IgM) or an antigen-binding fragment thereof. Each heavy chain is a heavy chain variable region (“HCVR”) or “VH ") and heavy chain invariant region (domain C H 1, C H 2 and C H Each light chain includes (including 3). Each light chain includes a light chain variable region ("LCVR" or "V L ") and light chain invariant region (C L Includes ). V H and V L The region can be further subdivided into a hypervariable region named the Complementarity Decision Region (CDR), which is sandwiched between a more conservative region referred to as the Framework Region (FR). Each V H and V L It includes three CDRs and four FRs arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments, the FRs of the antibody (or its antigen-binding fragment) may be identical to the human germline sequence, or may be naturally or artificially modified. The common amino acid sequence may be defined based on the parallel analysis of two or more CDRs.
[0031] Substitution of one or more CDR residues or omission of one or more CDRs is also possible. Antibodies in which one or two CDRs can be distributed for binding have been described in the scientific literature. Padlan et al. analyzed the contact regions between antibodies and their antigens based on published crystal structures and concluded that only about one-fifth to one-third of the CDR residues actually come into contact with the antigen (see reference [1995 FASEB J. 9:133-139]). Padlan also discovered many antibodies with one or two CDRs that lack an amino acid in contact with the antigen (see also Vajdos et al., 2002, J. Mol. Biol. 320:415-428).
[0032] CDR residues that do not come into contact with the antigen can be identified by molecular modeling and / or empirically based on previous studies (e.g., residues H60–H65 in CDRH2 are often not needed) from the region of the Kabat CDR located outside the Chotia CDR. If a CDR or its residue(s) are omitted, they are substituted with an amino acid occupying a corresponding position in another human antibody sequence or with a common sequence of such sequences. The position within the CDR for substitution and the amino acid to be substituted can also be selected empirically. Empirical substitutions can be conservative or non-conservative.
[0033] Human anti-MET antibodies or MET x MET bispecific antibodies useful herein may include one or more amino acid substitutions, insertions, and / or deletions in the framework compared to the corresponding germline sequence, and / or may include CDR regions of heavy and light chain variable domains. Such mutations can be easily identified by comparing the amino acid sequences in Table 1 with germline sequences available, for example, from published antibody sequence databases. Antibodies and their antigen-binding fragments derived from any one of the amino acid sequences provided in Table 1 are useful according to the present disclosure, wherein one or more amino acids within one or more framework regions and / or CDR regions may be mutated to corresponding residue(s) of the germline sequence from which the antibody is derived, mutated to corresponding residue(s) of another human germline sequence, or mutated to conservative amino acid substitutions of corresponding germline residue(s) (such sequence changes are collectively referred to herein as “germline mutations”). Those skilled in the art can readily produce a number of antibody and antigen-binding fragments comprising one or more individual germline mutations or combinations thereof, starting from the heavy and light chain variable region sequences according to Table 1. In a specific embodiment, V H and / or V L All of the framework and / or CDR residues within the domain are mutated back to residues found in the original germline sequence from which the antibody originated. In other embodiments, only specific residues are mutated back to the original germline sequence, for example, mutated residues found within the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or mutated residues found in CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residue(s) are mutated back to corresponding residue(s) of a different germline sequence (e.g., a germline sequence different from the original germline sequence from which the antibody originated). Additionally, the antibody of the present disclosure may contain any combination of two or more germline mutations within the framework and / or CDR region, for example, specific individual residues are mutated back to corresponding residues of a specific germline sequence, while specific other residues different from the original germline sequence are retained or mutated back to corresponding residues of a different germline sequence. Once obtained, antibody and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as in some cases), reduced immunogenicity, etc. Antibody and antigen-binding fragments obtained in this general manner are incorporated into the present disclosure.
[0034] MET-binding proteins, such as human anti-MET antibodies and MET x MET bispecific antibodies comprising any one variant of the HCVR, LCVR, and / or CDR amino acid sequences shown in Table 1 of the present invention having one or more conservative substitutions, are useful herein. For example, the present disclosure comprises MET x MET bispecific antibodies having an HCVR, LCVR, and / or CDR amino acid sequence having conservative amino acid substitutions, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., compared to any one of the HCVR, LCVR, and / or CDR amino acid sequences of Table 1.
[0035] The term “human antibody” as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The monoclonal antibodies of the present disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or by in vivo somatic mutations), e.g., in CDR, specifically in CDR3. However, the term “human antibody” as used herein is not intended to include monoclonal antibodies in which a CDR sequence derived from the germline of another mammalian species (e.g., mouse) is transplanted onto a human FR sequence.
[0036] As used herein, the term “multispecific antigen-binding molecule” refers to a bispecific, trispecific, or multispecific antigen-binding molecule and an antigen-binding fragment thereof. A multispecific antigen-binding molecule may contain an antigen-binding domain that is specific to a different epitope of a single target polypeptide or specific to the epitopes of two or more target polypeptides. A multispecific antigen-binding molecule may be a single multifunctional polypeptide or a complex of two or more polypeptides that are covalently or non-covalently linked to each other. The term “multispecific antigen-binding molecule” includes an antibody of the present disclosure that may be linked to or co-expressed with another functional molecule, for example, another peptide or protein. For example, an antibody or a fragment thereof may be functionally linked to one or more other molecular entities, such as a protein or its fragment (e.g., by chemical coupling, genetic fusion, non-covalent bonding, or otherwise), to produce a bispecific or multispecific antigen-binding molecule having a second binding specificity. According to the present disclosure, the term “multispecific antigen-binding molecule” also includes a bispecific, trispecific, or multispecific antibody or an antigen-binding fragment thereof. In certain embodiments, the antibody of the present disclosure is functionally linked to another antibody or an antigen-binding fragment thereof to produce a bispecific antibody having a second binding specificity. The bispecific and multispecific antibodies of the present disclosure are described elsewhere in this invention.
[0037] Terms such as "specifically binding" or "specifically binding to" refer to the formation of a complex by an antibody or its antigen-binding fragment with a relatively stable antigen under physiological conditions. Specific binding occurs at least about 1 x 10⁻⁶ -8 It can be characterized by an equilibrium dissociation constant of M or less (e.g., K D(The smaller the value, the tighter the binding). Methods for determining whether two molecules specifically bind to each other are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, etc. As described herein, antibodies have been identified by surface plasmon resonance (e.g., BIACORE™) that specifically bind to MET. Furthermore, multispecific antibodies that bind to one domain within MET and one or more additional antigens, and bispecific antibodies that bind to two different regions of MET, are nevertheless considered to be "specifically binding" antibodies as used herein.
[0038] As used herein, terms such as “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, etc., include any natural, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, terms such as “antigen-binding fragment” or “antibody fragment” of an antibody refer to one or more fragments of an antibody that possess the ability to bind to MET.
[0039] As used herein, "isolated antibody" is intended to refer to an antibody that is substantially free of another antibody (Ab) having different antigen specificity (e.g., an isolated antibody or fragment thereof that specifically binds to MET is substantially free of Ab that specifically binds to antigens other than MET).
[0040] The term "surface plasmon resonance" as used herein refers to an optical phenomenon that enables real-time analysis of interactions between biomolecules by detecting changes in protein concentration within a biosensor matrix using, for example, a BIACORE system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ).
[0041] Terms used at this institution "K D " is intended to refer to the equilibrium dissociation constant of a specific antibody-antigen interaction.
[0042] The term “epitope” refers to an antigenic determinant that interacts with a specific antigen-binding site in a variable region of an antibody molecule known as a paratope. A single antigen may have one or more epitopes. Therefore, different antibodies may bind to different regions on the antigen and have different biological efficacies. The term “epitope” also refers to a region on the antigen to which B and / or T cells respond. It also refers to a region of the antigen to which the antibody binds. Epitopes may be defined structurally or functionally. Functional epitopes are generally a subset of structural epitopes and have residues that directly contribute to the affinity of the interaction. Epitopes may also be three-dimensional structures (composed of non-linear amino acids). In certain embodiments, epitopes may include determinants that are a group of chemically active surfaces of molecules, such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural properties and / or specific charge properties.
[0043] When referring to a nucleic acid or a fragment thereof, the terms “substantially identical” or “substantially identical” indicate that there is nucleotide sequence identity in at least 90%, more preferably 95%, 96%, 97%, 98%, or 99% of the nucleotide bases measured by any well-known sequence identity algorithm such as FASTA, BLAST, or GAP, when appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand) are optimally aligned.
[0044] As applied to polypeptides, the terms “substantial similarity” or “substantially similar” mean that two peptide sequences share at least 90% sequence identity, and more preferably at least 95%, 98%, or 99% sequence identity, when optimally aligned, for example, by a GAP or BESTFIT program using default GAP weights. Preferably, non-identical residue positions differ by the amount of a conservative amino acid substitution. A “conservative amino acid substitution” is the substitution of an amino acid residue by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially alter the functional properties of the protein. If two or more amino acid sequences differ from each other by the amount of a conservative substitution, the percentage or degree of similarity may be up-adjusted to compensate for the conservative nature of the substitution. Means of making such adjustments are well known to those skilled in the art. For example, Pearson (1994) Methods Mol. Biol. See 24: 307-331 (which is incorporated herein by reference). Examples of the group of amino acids having side chains of similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate; and 7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acid substituents are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative substitution is any change having a positive value in the PAM250 log-likelihood matrix disclosed in the literature by Gonnet et al. (Gonnet et al., (1992) Science 256: 1443 45 (which is incorporated herein by reference). "Appropriately conservative" substitutions are any change that has a negative value in the PAM250 log-likelihood matrix. Sequence similarity for polypeptides is generally measured using sequencing software. Protein analysis software compares similar sequences using similarity measures assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as GAP and BESTFIT, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from organisms of different species, or between a wild-type protein and its mutate. See, for example, GCG version 6.1. Polypeptide sequences may also be compared using FASTA with default or recommended parameters (program in GCG version 6.1). FASTA (e.g., FASTA2 and FASTA3) provides alignment of the most overlapping regions between query and search sequences and the percentage of sequence identity (see Pearson (2000) cited above). Another preferred algorithm for comparing the sequences of the present disclosure with a database containing multiple sequences from different organisms is BLAST, specifically BLASTP or TBLASTN, which is a computer program using default parameters. See, for example, Altschul et al., (1990) J. Mol. Biol. 215: 403-410 and (1997) Nucleic Acids Res. 25:3389-3402 (each incorporated herein by reference).
[0045] The phrase "therapeutic effective dose" refers to the amount that produces the desired effect upon administration. The exact amount will vary depending on the purpose of the treatment and can be determined by a person skilled in the art using known techniques (see, for example, Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).
[0046] As used herein, the term "subject" refers to an animal, preferably a mammal, that requires improvement, prevention, and / or treatment of a disease or disorder such as chronic infection, cancer, or autoimmune disease.
[0047] II. Radiolabeled immunoconjugate of MET antibody for immuno-PET imaging
[0048] A radiolabeled antigen-binding protein that binds to a MET protein is provided herein. In some embodiments, the radiolabeled antigen-binding protein comprises an antigen-binding protein covalently bound to one or more chelating moieties, which are chemical moieties capable of chelating a positron emitter.
[0049] In some embodiments, an antigen-binding protein that binds to a MET, e.g., an anti-MET antibody or a MET x MET bispecific antibody is provided herein, wherein the aforementioned antigen-binding protein that binds to the MET is covalently bonded to one or more moieties having the following structure:
[0050] -LM Z
[0051] (wherein L is a chelation moiety; M is a positron emitter; z is independently 0 or 1 in each case; and at least one of z is 1).
[0052] In some embodiments, the radiolabeled antigen-binding protein is a compound of formula (I):
[0053] MLA-[LM Z ] k
[0054] Chemical formula (I)
[0055] (In the formula, A is a protein that binds to MET; L is a chelating moiety; M is a positron emitter; z is 0 or 1; and k is an integer from 0 to 30. In some embodiments, k is 1).
[0056] In a specific embodiment, the radiolabeled antigen-binding protein is of the chemical formula ( II It is a compound of:
[0057] A-[LM] k
[0058] Chemical formula (II)
[0059] (In the formula, A is a protein that binds to MET; L is a chelating moiety; M is a positron emitter; and k is an integer from 1 to 30).
[0060] In some embodiments, a composition comprising a composite having the following structure is provided herein:
[0061] AL k
[0062] (In the formula, A is a protein that binds to MET; L is a chelation moiety; k is an integer from 1 to 30; and the conjugate is chelated in an amount sufficient to provide specific activity suitable for clinical PET imaging by a positron emitter).
[0063] Appropriate binding proteins, chelation moiety, and positron emitters are provided below.
[0064] A. MET-binding protein
[0065] Suitable MET-binding proteins are proteins that specifically bind to MET, including those described in U.S. Patent Publication No. 2018-0134794, the whole of which is incorporated herein by reference. Amino acid sequence identifiers of exemplary anti-MET antibodies useful herein are listed in Table 1 of U.S. Patent Publication No. 2018-0134794, and amino acid sequence identifiers of exemplary MET x MET bispecific antibodies useful herein are listed in Table 5 of U.S. Patent Publication No. 2018-0134794. Both tables are included below as Table 1 and Table 2, respectively.
[0066]
[0067]
[0068] * The number specified in parentheses below the bispecific antibody identifier (e.g., "No. 10") represents the bispecific antibody number depicted in the MET x MET bispecific antibody matrix of FIG. 1, U.S. Patent Publication No. 2018-0134794.
[0069] Table 1 presents the amino acid sequence identifiers of the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3), and light chain complementarity determining region (LCDR1, LCDR2, and LCDR3) of an exemplary anti-MET antibody.
[0070] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising HCVR, comprising an amino acid sequence selected from any one of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to it.
[0071] In some embodiments, the binding protein is an antibody or antigen binding fragment comprising the LCVR amino acid sequence shown in Table 1 or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to it.
[0072] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising an HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising any one of the HCVR amino acid sequences listed in Table 1 paired with the LCVR amino acid sequence shown in Table 1. According to certain embodiments, the present disclosure provides an antibody or an antigen-binding fragment thereof comprising an HCVR / LCVR amino acid sequence pair contained in any one of the exemplary anti-MET antibodies listed in Table 1. In a specific embodiment, the HCVR / LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs 2 / 138, 10 / 138, 18 / 138, 26 / 138, 34 / 138, 42 / 138, 50 / 138, 58 / 138, 66 / 138, 74 / 138, 82 / 138, 90 / 138, 98 / 138, 106 / 138, 114 / 138, 122 / 138, and 130 / 138. In a specific embodiment, the HCVR / LCVR amino acid sequence pair is selected from one of SEQ ID NOs 58 / 138 (e.g., H4H13306P2) and 82 / 138 (e.g., H4H13312P2).
[0073] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any one of the HCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0074] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any one of the HCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0075] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any one of the HCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0076] In some embodiments, the binding protein is an antibody or antigen binding fragment comprising a light chain CDR1 (LCDR1) comprising the amino acid sequence shown in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0077] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a light chain CDR2 (LCDR2) comprising the amino acid sequence shown in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0078] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a light chain CDR3 (LCDR3) having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to the amino acid sequence shown in Table 1.
[0079] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising an HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3) comprising any one of the HCDR3 amino acid sequences listed in Table 1 paired with the LCDR3 amino acid sequence shown in Table 1. According to certain embodiments, the present disclosure provides an antibody or an antigen-binding fragment thereof comprising an HCDR3 / LCDR3 amino acid sequence pair contained in any one of the exemplary anti-MET antibodies listed in Table 1. In a specific embodiment, the HCDR3 / LCDR3 amino acid sequence pair is SEQ ID NO. 8 / 144 (e.g., H4H13290P2), 16 / 144 (e.g., H4H13291P2), 24 / 144 (H4H13295P2), 32 / 144 (H4H13299P2), 40 / 144 (H4H13300P2), 48 / 144 (H4H13301P2), 56 / 144 (H4H13302P2), 64 / 144 (H4H13306P2), 72 / 144 (H4H13309P2), 80 / 144 (H4H13311P2), 88 / 144 (H4H13312P2), It is selected from the group consisting of 96 / 144(H4H13313P2), 104 / 144(H4H13316P2), 112 / 144(H4H13318P2), 120 / 144(H4H13319P2), 128 / 144(H4H13325P2), and 136 / 144(H4H13331P2).
[0080] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any one of the exemplary anti-MET antibodies listed in Table 1. In a specific embodiment, the set of amino acid sequences HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 is SEQ ID NO. 4-6-8-140-142-144 (e.g., H4H13290P2), 12-14-16-140-142-144 (e.g., H4H13291P2), 20-22-24-140-142-144 (H4H13295P2), 28-30-32-140-142-144 (H4H13299P2), 36-38-40-140-142-144 (H4H13300P2), 44-44-48-140-142-144 (H4H13301P2), 52-54-56-140-142-144(H4H13302P2), 60-62-64-140-142-144(H4H13306P2), 68-70-72-140-142-144(H4H13309P2), 76-78-80-140-142-144(H4H13311P2), 84-86-88-140-142-144(H4H13312P2), 92-94-96-140-142-144(H4H13313P2), 100-102-104-140-142-144(H4H13316P2), It is selected from the group consisting of 108-110-112-140-142-144(H4H13318P2), 116-118-120-140-142-144(H4H13319P2), 124-126-128-140-142-144(H4H13325P2), and 132-134-136-140-142-144(H4H13331P2).
[0081] In some embodiments, the binding protein is an antibody or antigen-binding fragment comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within an HCVR / LCVR amino acid sequence pair as defined by any one of the exemplary anti-MET antibodies listed in Table 1. For example, in some embodiments, the binding protein is SEQ ID NO. 2 / 138 (e.g., H4H13290P2), 10 / 138 (e.g., H4H13291P2), 18 / 138 (H4H13295P2), 26 / 138 (H4H13299P2), 34 / 138 (H4H13300P2), 42 / 138 (H4H13301P2), 50 / 138 (H4H13302P2), 58 / 138 (H4H13306P2), 66 / 138 (H4H13309P2), 74 / 138 (H4H13311P2), 82 / 138 (H4H13312P2), It is an antibody or antigen-binding fragment comprising a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences contained within an HCVR / LCVR amino acid sequence pair selected from the group consisting of 90 / 138(H4H13313P2), 98 / 138(H4H13316P2), 106 / 138(H4H13318P2), 114 / 138(H4H13319P2), 122 / 138(H4H13325P2), and 130 / 138(H4H13331P2).
[0082] Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within specific HCVR and / or LCVR amino acid sequences useful herein. Exemplary definitions that can be used to identify the boundaries of CDRs include, for example, the Kabat definition, the Chothia definition, and the AbM definition. Under general conditions, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. For example, Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol . 273:927-948(1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86 Refer to :9268-9272 (1989). Public databases can also be used to identify CDR sequences within antibodies.
[0083] In some embodiments, the binding protein is an antibody or its antigen-binding fragment that competes with the antibody or its antigen-binding fragment comprising the CDR of HCVR and the CDR of LCVR to specifically bind to MET, wherein each of HCVR and LCVR has an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0084] Table 2 presents amino acid sequence identifiers for the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3), and light chain complementarity determining region (LCDR1, LCDR2, and LCDR3) of the first antigen binding domain (D1) and the second antigen binding domain (D2) of an exemplary MET x MET bispecific antibody.
[0085] The individual anti-MET antigen-binding domains used to construct the bispecific antibodies useful herein are derived from the various divalent, monospecific anti-MET antibodies described in Examples 1 to 3 of U.S. Publication No. 2018-0134794. All anti-MET antibodies described herein contain the same ("common") light chain (including the light chain variable region [LCVR] amino acid sequence of SEQ ID NO. 138, and the light chain CDR [LCDR1, LCDR2, and LCDR3] amino acid sequences of SEQ ID NOs. 140, 142, and 144). Additionally, all bispecific antibodies contain a "D2" arm derived from the exemplary anti-MET antibody H4H13312P2. Accordingly, both antigen-binding domains (D1 and D2) of all bispecific antibodies described in this embodiment include this common light chain variable region, and all D2 binding arms include a heavy chain variable region derived from H4H13312P2; however, the bispecific antibodies differ from each other in their D1 heavy chain variable region (HCVR) and heavy chain CDR (HCDR). D1 and D2 are derived from different anti-MET antibodies and consequently bind to separate epitopes on the MET extracellular domain. That is, D1 binds to a first epitope of human MET, e.g., an epitope comprising amino acids 192 to 204 of SEQ ID NO. 155; and D2 binds to a second epitope of human MET comprising amino acids 305 to 315 and 421 to 455 of SEQ ID NO. 155.
[0086] As used herein, the term “antigen-binding domain” means any peptide, polypeptide, nucleic acid molecule, scaffold-type molecule, peptide display molecule, or construct containing a polypeptide capable of specifically binding to a specific antigen of interest (e.g., human MET). As used herein, the terms “specifically binding” or similar terms refer to such antigen-binding domains having a dissociation constant (K) of 500 pM or less D It means that it forms a complex with a specific antigen characterized by ) and does not bind to other unrelated antigens under normal test conditions. An "unrelated antigen" is a protein, peptide, or polypeptide that has less than 95% amino acid identity with respect to one another.
[0087] Exemplary categories of antigen-binding domains that may be used in the context of the present disclosure include antibodies, antigen-binding portions of antibodies, peptides that specifically interact with a specific antigen (e.g., peptibodias), receptor molecules that specifically interact with a specific antigen, proteins comprising ligand-binding portions of receptors that specifically bind to a specific antigen, antigen-binding scaffolds (e.g., engineered ankyrin repeat proteins (DARPin), HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, and other scaffolds based on naturally occurring repeat proteins, etc. [e.g., Boersma and Pluckthun, 2011, Curr. Opin. Biotechnol. 22:849-857, and refer to the references cited in the literature]) and aptamers or parts thereof.
[0088] Methods for determining whether two molecules specifically bind to each other are well known in the field, including, for example, equilibrium dialysis and surface plasmon resonance. For example, the antigen-binding domain used in the context of the present disclosure comprises a polypeptide that binds to a specific antigen (e.g., target molecule [T] or internalization effector protein [E]) or a portion thereof with a KD of less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, less than about 10 pM, less than about 5 pM, less than about 4 pM, less than about 2 pM, less than about 1 pM, less than about 0.5 pM, less than about 0.2 pM, less than about 0.1 pM, or less than about 0.05 pM, as determined by surface plasmon resonance analysis.
[0089] The term "surface plasmon resonance" as used herein refers to an optical phenomenon that enables the analysis of real-time interactions by detecting changes in protein concentration within a biosensor matrix using, for example, a BIAcore system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
[0090] As used herein, the term "KD" refers to the equilibrium dissociation constant of a particular protein-protein interaction (e.g., antibody-antigen interaction). Unless otherwise indicated, K as manifested by antibodies useful herein D The value is K determined by surface plasmon resonance analysis at 25°C or 37°C. D Refers to the value.
[0091] As indicated above, the "antigen-binding domain" (D1 and / or D2) may comprise or consist of an antibody or an antigen-binding fragment of an antibody. As used herein, the term "antibody" means any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that specifically binds to or interacts with a specific antigen (e.g., human MET). The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, namely two heavy chains (H) and two light chains (L) interconnected by disulfide bonds, as well as polymers thereof (e.g., IgM). Each heavy chain is a heavy chain variable region (HCVR or V in this application). H It includes the heavy chain invariant region (abbreviated as ) and the heavy chain invariant region. The heavy chain invariant region consists of three domains C H 1, C H 2 and C H 3. Each light chain includes a light chain variable region (LCVR or V in this application). L It includes the light chain invariant region (abbreviated as ). The light chain invariant region includes a single domain (C L 1). V H Area and V L The region can be further subdivided into a hypervariable region (referred to as the Complementarity Decision Region (CDR)) sandwiched between a more conservative region (referred to as the Framework Region (FR)). Each V H and V L It comprises three CDRs and four FRs arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In other embodiments, the FRs (or antigen-binding portions of the antibody) of the antibody provided herein may be identical to the human germline sequence, or may be naturally or artificially modified. The common amino acid sequence may be defined based on the parallel analysis of two or more CDRs.
[0092] The D1 and / or D2 components of the bispecific antigen-binding molecule useful herein may comprise or consist of an antigen-binding fragment of the whole antibody molecule. As used herein, terms such as “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, and similar terms include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. The antigen-binding fragment of an antibody may be derived from the whole antibody molecule using any suitable standard technique, e.g., proteolytic digestion or recombinant genetic engineering techniques including the manipulation and expression of DNA encoding an antibody variable domain and optionally an invariant domain. Such DNA may be known and / or readily available from, for example, commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or synthesized. Such DNA can be sequenced and manipulated using chemical or molecular biology techniques, for example, to arrange one or more variable and / or constant domains into an appropriate configuration, or to introduce codons, generate cysteine residues, modify, add, or delete amino acids, etc.
[0093] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) short-chain Fv(scFv) molecules; (vi) dAb fragments; and (vii) amino acid residues mimicking the hypervariable region of an antibody (e.g., the isolated complementarity determining region (CDR) such as the CDR3 peptide), or minimal recognition units composed of a restricted FR3-CDR3-FR4 peptide. Other engineered molecules, e.g., domain-specific antibodies, mono-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-transplant antibodies, diabodies, triabodidies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, divalent nanobodies, etc.), small modular immunotherapies (SMIPs), and shark variable IgNAR domains, etc. are also included in the expression "antigen-binding fragments" as used herein.
[0094] The antigen-binding fragment of an antibody generally contains at least one variable domain. This variable domain may be of any size or amino acid composition and will generally contain at least one CDR adjacent to or in the same frame as one or more framework sequences. V L V combined with the domain H In an antigen-binding fragment having a domain, V H and V L Domains can be positioned relative to each other in any appropriate arrangement. For example, the variable domain is a dimer, V H -V H , V H V L or V L -V L It may contain a dimer. Alternatively, the antigen-binding fragment of the antibody is monomer V H or V L It can include domains.
[0095] In a specific embodiment, the antigen-binding fragment of the antibody may comprise at least one variable domain covalently bonded to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within the antigen-binding fragment of the antibody of the present disclosure include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C LIn any configuration of variable and invariant domains comprising any exemplary configurations listed above, such variable and invariant domains may be directly connected to one another or connected by wholly or partially hinge or linker regions. A hinge region may consist of at least two amino acids (e.g., 5, 10, 15, 20, 40, 60 or more) resulting in a flexible or semi-flexible linkage between adjacent variable and / or invariant domains of a single polypeptide molecule. Additionally, the antigen-binding fragment may be a homo-dimer or hetero-dimer (or other multimer) of any variable and invariant domain configuration listed above, and / or one or more monomers V H or V L It may be included by non-covalent bonding with the domain (e.g., by disulfide bond(s)).
[0096] In some embodiments, the binding protein is a bispecific antigen-binding molecule comprising or composed of a human antibody and / or recombinant human antibody, or a fragment thereof. As used herein, the term “human antibody” includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences. However, human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or by in vivo somatic mutations), e.g., in CDRs, and particularly in CDR3s. However, as used herein, the term “human antibody” is not intended to include antibodies in which a CDR sequence derived from the germline of another mammalian species, e.g., mouse, is grafted onto a human framework sequence.
[0097] As used herein, the term “recombinant human antibody” is intended to include all human antibodies produced, expressed, generated, or isolated by recombinant means, e.g., antibodies expressed using a recombinant expression vector transformed into a host cell (described in detail below), antibodies isolated from a recombinant human antibody library (described in detail below), antibodies isolated from animals (e.g., mice) into which the human immunoglobulin gene has been introduced (e.g., mice) (e.g., see Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies produced, expressed, generated, or isolated by any other means including splicing of the human immunoglobulin gene sequence to another DNA sequence. Such recombinant human antibodies have variable and constant regions derived from the human germline immunoglobulin sequence. However, in some embodiments, since these recombinant human antibodies undergo in vitro mutagenesis (or in vivo somatic mutagenesis in the case where animals genetically modified for the human Ig sequence are used), the V of the recombinant antibody H and V L The amino acid sequence of the region is human gonad V H and V L They are derived from and related to sequences, but may not naturally exist within the human antibody germline repertoire in vivo.
[0098] Methods for preparing bispecific antibodies are known in the art and can be used to construct bispecific antigen-binding molecules useful for the conjugates disclosed herein. Exemplary bispecific formats that may be used in the context of the present invention include, for example, scFv-series or diabody bispecific formats, IgG-scFv fusion, dual variable domain (DVD)-Ig, quadroma, knobs-into-holes, common light chains (e.g., common light chains having knobs-into-holes), CrossMab, CrossFab, (SEED)body, leucine zipper, duobody, IgG1 / IgG2, dual-acting Fab (DAF)-IgG, and Mab2 bispecific formats, but are not limited thereto (to review the aforementioned formats, refer, for example, to Klein et al., 2012, mAbs 4:6, 1-11 and the references cited therein).
[0099] Exemplary antigen-binding domains (D1 and D2) that may be included in the MET x MET bispecific antigen-binding molecule useful herein include antigen-binding domains derived from any one of the anti-MET antibodies disclosed in Table 1. For example, the present disclosure includes a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising an amino acid sequence selected from any one of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity therewith.
[0100] The binding protein may be a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising an LCVR having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to the amino acid sequence shown in Table 1.
[0101] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising an HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising any one of the HCVR amino acid sequences listed in Table 1 paired with the LCVR amino acid sequence shown in Table 1.
[0102] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any one of the HCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0103] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any one of the HCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0104] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any one of the HCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0105] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a light chain CDR1 (LCDR1) comprising the LCDR1 amino acid sequence shown in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0106] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a light chain CDR2 (LCDR2) comprising the LCDR2 amino acid sequence shown in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0107] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a light chain CDR3 (LCDR3) comprising the LCDR3 amino acid sequence shown in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0108] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising an HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3) comprising any one of the HCDR3 amino acid sequences listed in Table 1 paired with the LCDR3 amino acid sequence shown in Table 1.
[0109] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any one of the exemplary anti-MET antibodies listed in Table 1.
[0110] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 or D2 antigen-binding domain comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within an HCVR / LCVR amino acid sequence pair as defined by any one of the exemplary anti-MET antibodies listed in Table 1.
[0111] A MET x MET bispecific antigen-binding molecule useful herein may comprise a D1 antigen-binding domain derived from any one of the anti-MET antibodies of Table 1 and a D2 antigen-binding domain derived from any other anti-MET antibody of Table 1. A non-limiting example of the MET x MET bispecific antibody of the present disclosure is illustrated in FIG. 1 of U.S. Patent Publication No. 2018-0134794, which illustrates 272 exemplary components of MET x MET bispecific antibodies. Each cell of the matrix numbered (1 to 272) identifies a unique bispecific antibody comprising a “D1” antigen-binding domain and a “D2” antigen-binding domain, wherein the D1 antigen-binding domain comprises an immunoglobulin variable domain (HCVR / LCVR amino acid sequence pair) or CDR derived from the corresponding anti-MET antibody listed along the Y-axis, and the D2 antigen-binding domain comprises an immunoglobulin variable domain (HCVR / LCVR amino acid sequence pair) or CDR derived from the corresponding anti-MET antibody listed along the X-axis. Thus, for example, the MET x MET bispecific antigen-binding molecule “No. 10” shown in the matrix comprises a D1 antigen-binding domain comprising an HCVR / LCVR pair or a 6-CDR set derived from the exemplary anti-MET antibody H4H13290P2, or a D2 antigen-binding domain comprising an HCVR / LCVR pair or a 6-CDR set derived from the exemplary anti-MET antibody H4H13321P2. An additional example of the MET x MET bispecific antibody provided herein is described in Example 4 of U.S. Patent Publication No. 2018-0134794.
[0112] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 antigen-binding domain and a D2 antigen-binding domain, wherein the D1 antigen-binding domain comprises an HCVR / LCVR amino acid sequence pair having a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to SEQ ID NO. 58 / 138, or SEQ ID NO. 60-62-64-140-142-144, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to SEQ ID NO. 60-62-64-140-142-144, or a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to SEQ ID NO. 82 / 138, or at least 90%, at least 95%, at least 98%, or at least 99% with respect to It includes a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising a pair of HCVR / LCVR amino acid sequences of substantially similar sequences having sequence identity, or sequence number 84-86-88-140-142-144, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0113] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 antigen-binding domain and a D2 antigen-binding domain, wherein the D1 antigen-binding domain comprises an HCVR / LCVR amino acid sequence pair having a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to SEQ ID NO. 18 / 138, or SEQ ID NO. 20-22-24-140-142-144, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to SEQ ID NO. 20-22-24-140-142-144, or a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect to SEQ ID NO. 82 / 138, or at least 90%, at least 95%, at least 98%, or at least 99% with respect to It includes a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising a pair of HCVR / LCVR amino acid sequences of substantially similar sequences having sequence identity, or sequence number 84-86-88-140-142-144, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto.
[0114] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 antigen-binding domain and a D2 antigen-binding domain, wherein the D1 antigen-binding domain comprises a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 58 / 138 or SEQ ID NO. 60-62-64-140-142-144, and the D2 antigen-binding domain comprises a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 82 / 138 or SEQ ID NO. 84-86-88-140-142-144. An exemplary MET x MET bispecific antibody having these sequence characteristics is designated as H4H14639D (also referred to as bispecific antibody number 122), which includes D1 derived from H4H13306P2 and D2 derived from H4H13312P2 (see Table 2 of the present invention).
[0115] In some embodiments, the binding protein is a MET x MET bispecific antigen-binding molecule comprising a D1 antigen-binding domain and a D2 antigen-binding domain, wherein the D1 antigen-binding domain comprises a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 18 / 138 or SEQ ID NO. 20-22-24-140-142-144, and the D2 antigen-binding domain comprises a heavy chain and light chain CDR set (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 82 / 138 or SEQ ID NO. 84-86-88-140-142-144. An exemplary MET x MET bispecific antibody having these sequence characteristics is the bispecific antibody designated as H4H14635D (also referred to as bispecific antibody number 42), which comprises D1 derived from H4H13295P2 and D2 derived from H4H13312P2 (see Table 2 of the present invention).
[0116] The bispecific antigen-binding molecule useful herein may also comprise one or more multimerization components. The multimerization component may function to maintain the binding between the antigen-binding domains (D1 and D2). As used herein, "multimerization component" is any macromolecule, protein, polypeptide, peptide, or amino acid having the ability to bind to a second multimerization component of the same or similar structure or composition. For example, the multimerization component is immunoglobulin C HIt may be a polypeptide comprising three domains. Non-limiting examples of the multimerization component are the Fc portion of immunoglobulins, e.g., isotypes IgG1, IgG2, IgG3, and IgG4, and the Fc domain of IgG selected from any homogenic factor type within each isotype group. In certain embodiments, the multimerization component is an amino acid sequence of length 1 to about 200 amino acids containing an Fc fragment or at least one cysteine residue. In other embodiments, the multimerization component is a peptide containing a cysteine residue or a short cysteine. Other multimerization domains comprise a peptide or polypeptide comprising or composed of a leucine zipper, a helical-loop motif, or a double coil motif.
[0117] In a specific embodiment, the bispecific antigen-binding molecule useful herein comprises two multimerized domains M1 and M2, wherein D1 is attached to M1 and D2 is attached to M2, and the binding of M2 and M1 facilitates the physical connection of D1 and D2 to each other in a single bispecific antigen-binding molecule. In a specific embodiment, M1 and M2 are identical to each other. For example, M1 may be an Fc domain having a specific amino acid sequence, and M2 is an Fc domain having the same amino acid sequence as M1. Alternatively, M1 and M2 may differ from each other at one or more amino acid positions. For example, M1 is a first immunoglobulin (Ig) C H It may include 3 domains, and M2 is the 2nd Ig C H It may include 3 domains, wherein the first and second Ig C H The three domains differ from each other by at least one amino acid, and the difference of at least one amino acid reduces the binding of the targeting construct to protein A compared to a reference construct having the same M1 and M2 sequences. In one embodiment, the Ig C of M1 H The 3 domain binds to protein A, and M2's Ig C HDomain 3 contains mutations that reduce or eliminate Protein A binding, such as the H95R alteration (based on IMGT exon numbering; H435R according to EU numbering). C of M2 H 3 may additionally include the Y96F change (according to IMGT; Y436F according to the EU). C of M2 H Additional changes that may be found within 3 include the following: for the IgG1 Fc domain, D16E, L18M, N44S, K52N, V57M, and V82I (according to IMGT; according to EU, D356E, L358M, N384S, K392N, V397M, and V422I); for the IgG2 Fc domain, N44S, K52N, and V82I (according to IMGT; according to EU, N384S, K392N, and V422I); and for the IgG4 Fc domain, Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (according to IMGT; according to EU, Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I).
[0118] In some embodiments, the binding protein may be “isolated.” As used herein, “isolated bispecific antigen-binding molecule” means a bispecific antigen-binding molecule identified and isolated from / or recovered from at least one component of the natural environment. For example, a bispecific antibody isolated or removed from at least one component of an organism, or from a tissue or cell in which the antibody is produced, is an “isolated bispecific antibody” suitable for the purposes of the present invention. The isolated bispecific antigen-binding molecule also includes molecules in situ within recombinant cells. The isolated bispecific antigen-binding molecule is a molecule that has undergone at least one purification or isolation step. According to certain embodiments, the isolated bispecific antigen-binding molecule may substantially not contain other cellular material and / or chemicals.
[0119] A bispecific antigen-binding molecule or its antigen-binding domain (D1 and / or D2) useful herein may include one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of heavy and light chain variable domains when compared to the corresponding germline sequence from which the antigen-binding protein or antigen-binding domain is derived. Such mutations can be easily identified by comparing the amino acid sequences of Table 1 with germline sequences available, for example, from a published antibody sequence database. A bispecific antigen-binding molecule or its antigen-binding domain (D1 and / or D2) useful herein derived from any one of the amino acid sequences shown in Tables 1 and 2 may include one or more amino acids within one or more framework regions and / or CDR regions (such sequence changes are collectively referred to herein as “germline mutations”) that may be mutated to the corresponding residue(s) of the germline sequence from which the antibody is derived, mutated to the corresponding residue(s) of another human germline sequence, or mutated to a conservative amino acid substitution of the corresponding germline residue(s).
[0120] Those skilled in the art can readily produce a plurality of bispecific antigen-binding molecules or their antigen-binding domains (D1 and / or D2), comprising one or more individual germline mutations or combinations thereof, starting from the heavy and light chain variable region sequences of Tables 1 and 2. In a specific embodiment, V H and / or V L All of the framework and / or CDR residues within the domain are mutated back to residues found in the original germline sequence from which the antibody originated. In other embodiments, only specific residues are mutated back to the original germline sequence, for example, mutated residues found within the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or mutated residues found in CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residue(s) are mutated back to corresponding residue(s) of a different germline sequence (e.g., a germline sequence different from the original germline sequence from which the antibody originated).
[0121] In some embodiments, the binding protein may contain any combination of two or more germline mutations within the framework and / or CDR region, for example, wherein specific individual residues are mutated to corresponding residues of a specific germline sequence, while specific other residues different from the original germline sequence are retained or mutated to corresponding residues of a different germline sequence. For example, a bispecific antigen-binding molecule or its antigen-binding fragment (D1 and / or D2) containing one or more germline mutations may be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, (in some cases) improved or enhanced antagonistic or activating biological properties, reduced immunogenicity, etc. A bispecific antigen-binding molecule or its antigen-binding domain (D1 and / or D2) obtained in this general manner is incorporated within the present disclosure.
[0122] In some embodiments, the binding protein is an anti-MET antibody or a bispecific antigen-binding molecule comprising any one variant of the HCVR, LCVR, and / or CDR amino acid sequences provided in Tables 1 and 2. Exemplary variants included in these embodiments include any one variant of the HCVR, LCVR, and / or CDR amino acid sequences of Tables 1 and 2 having one or more conservative substitutions. For example, the binding protein useful herein includes an anti-MET antibody and a MET x MET bispecific antigen-binding molecule having an HCVR, LCVR, and / or CDR amino acid sequence having, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, conservative amino acid substitutions compared to the HCVR, LCVR, and / or CDR amino acid sequences presented in Table 1 of the present invention.
[0123] Exemplary variants also include variants having substantial sequence identity with respect to any one of the HCVR, LCVR, and / or CDR amino acid sequences provided in Table 1. As used herein in the context of amino acid sequences, the terms “substantial identity” or “substantively identical” mean that two amino acid sequences share at least 95%, 98%, or 99% sequence identity when optimally aligned by the GAP or BESTFIT program using default gap weights, for example. In certain embodiments, non-identical residue positions differ by a conservative amino acid substitution. A “conservative amino acid substitution” is the substitution of an amino acid residue by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, a conservative amino acid substitution will not substantially alter the functional properties of the protein. If two or more amino acid sequences differ from each other by a conservative substitution, the percentage of sequence identity or the degree of similarity may be upscaled to compensate for the conservative nature of the substitution. Means of making such adjustments are well known to those skilled in the art. For example, see Pearson (1994) Methods Mol. Biol. 24: 307-331 (which is incorporated herein by reference). Examples of the group of amino acids having side chains of similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartate and glutamate; and (7) sulfur-containing side chains: cysteine and methionine.Preferred conservative amino acid substituents are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative substitution is any change having a positive value in the PAM250 log-likelihood matrix disclosed in the literature by Gonnet et al. (Gonnet et al. , (1992) Science 256: 1443-1445 (incorporated herein by reference). A “suitable conservative” permutation is any change that has a negative value in the PAM250 log-likelihood matrix.
[0124] Sequence identity between two different amino acid sequences is typically measured using sequencing software. Sequencing software compares similar sequences using similarity measures assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as Gap and Bestfit, which can be used with default parameters to determine sequence homology or identity between closely related polypeptides, such as homologous polypeptides from organisms of different species, or between a wild-type protein and its mutate. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment of the most overlapping regions between the query and search sequences and the percentage of sequence identity (see Pearson (2000) cited above). Another preferred algorithm for comparing the sequences provided herein with a database containing multiple sequences of different organisms is BLAST, a computer program using default parameters, in particular BLASTP or TBLASTN. For example, Altschul et al., (1990) J. Mol. Biol. 215:403-410 and Altschul et al., (1997) Nucleic Acids Res. 25:3389-402 (each incorporated herein by reference).
[0125] In some embodiments, the binding protein is an anti-MET antibody or a MET x MET bispecific antigen-binding protein comprising an Fc domain containing one or more mutations that enhance or attenuate antibody binding to the FcRn receptor at acidic pH compared to neutral pH, for example. For example, the anti-MET antibody and the MET x MET bispecific antigen-binding protein have C of the Fc domain.H 2 or C H It includes mutations in three regions, wherein the mutation(s) increase the affinity of the Fc domain for FcRn in an acidic environment (e.g., in endosomes where the pH is in the range of about 5.5 to 6.0). Such mutations may increase the serum half-life of the antibody when administered to animals. Non-limiting examples of such Fc modifications are, for example, modifications at position 250 (e.g., E or Q); modifications at positions 250 and 428 (e.g., L or F); modifications at position 252 (e.g., L / Y / F / W or T), position 254 (e.g., S or T), and position 256 (e.g., S / R / Q / E / D or T); or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or position 434 (e.g., H / F or Y); or variations at position 250 and / or 428; or variations at position 307 or 308 (e.g., 308F, V308F) and position 434. In one embodiment, the variations include 428L (e.g., M428L) and 434S (e.g., N434S) variations; 428L, 259I (e.g., V259I), and 308F (e.g., V308F) variations; 433K (e.g., H433K) and 434 (e.g., 434Y) variations; 252, 254, and 256 (e.g., 252Y, 254T, and 256E) variations; 250Q and 428L variations (e.g., T250Q and M428L); and includes 307 and / or 308 variations (e.g., 308F or 308P).
[0126] For example, the binding protein may be an anti-MET antibody and a MET x MET bispecific antigen-binding protein comprising an Fc domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the aforementioned Fc domain mutations and other mutations within the antibody variable domain useful herein are considered to be within the scope of the present disclosure.
[0127] In some embodiments, the binding protein is an antibody or its antigen-binding fragment that cross-competes with a reference antibody or its antigen-binding fragment comprising the CDR of HCVR and the CDR of LCVR to bind to MET, wherein each of HCVR and LCVR has an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0128] Binding protein characteristics
[0129] In some embodiments, the binding protein is an isolated antibody or antigen-binding fragment that binds to monomeric human MET with high affinity. For example, a binding protein useful herein is a K less than about 230 nM when measured by surface plasmon resonance at 25°C or 37°C using a assay format as defined, for example, in Example 3 of U.S. Patent Publication No. 2018-0134794, or a substantially similar assay. DIt comprises an anti-MET antibody that binds to monomeric human MET (e.g., hMET.mmh). According to a specific embodiment, the anti-MET antibody useful herein is, for example, when measured by surface plasmon resonance using a assay format as defined in Example 3 of U.S. Patent Publication No. 2018-0134794 or a substantially similar assay, K at 37°C less than about 230 nM, less than about 200 nM, less than about 150 nM, less than about 100 nM, less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 10 nM, less than about 8 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, or less than about 3 nM. D The monomer binds to human MET.
[0130] In some embodiments, the binding protein is an antibody or antigen-binding fragment that binds to monomeric human MET (e.g., hMET.mmh) with a dissociation half-life (t½) greater than about 1 minute when measured by surface plasmon resonance at 25°C or 37°C using a assay format or substantially similar assay as defined in Example 3 of U.S. Patent Publication No. 2018-0134794. According to a specific embodiment, these anti-MET antibodies bind to monomeric human MET for more than 1 minute, more than 2 minutes, more than 4 minutes, more than 6 minutes, more than 8 minutes, more than 10 minutes, more than 12 minutes, more than 14 minutes, more than 16 minutes, more than 18 minutes, or more than 20 minutes or more than t½ when measured by surface plasmon resonance using, for example, the assay format defined in Example 3 of U.S. Patent Publication No. 2018-0134794.
[0131] In some embodiments, the binding protein is an antibody or its antigen-binding fragment that binds with high affinity to dimeric human MET (e.g., hMET.mFc). For example, such anti-MET antibodies have a K of less than about 3 nM when measured by surface plasmon resonance at 25°C or 37°C using a assay format as defined, for example, in Example 3 of U.S. Patent Publication No. 2018-0134794, or a substantially similar assay. D It binds to dimeric human MET. The anti-MET antibodies useful herein are, for example, when measured by surface plasmon resonance using a assay format as defined in Example 3 of U.S. Patent Publication No. 2018-0134794 or a substantially similar assay, K at 37°C less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 0.9 nM, less than about 0.8 nM, less than about 0.7 nM, less than about 0.6 nM, less than about 0.5 nM, less than about 0.4 nM, less than about 0.3 nM, or less than about 0.25 nM. D It can bind to dimeric human MET.
[0132] In some embodiments, the binding protein is an antibody or antigen-binding fragment that binds to dimeric human MET (e.g., hMET.mFc) with a dissociation half-life (t½) greater than about 4 minutes when measured by surface plasmon resonance at 25°C or 37°C using a assay format or substantially similar assay as defined in Example 3 of U.S. Patent Publication No. 2018-0134794. According to a specific embodiment, the anti-MET antibody useful herein binds to dimeric human MET for more than 4 minutes, more than 5 minutes, more than 10 minutes, more than 20 minutes, more than 30 minutes, more than 40 minutes, more than 50 minutes, more than 60 minutes, more than 70 minutes, more than 80 minutes, more than 90 minutes, more than 100 minutes, more than 105 minutes, or more than 105 minutes or more when measured by surface plasmon resonance using, for example, the assay format defined in Example 3 of U.S. Patent Publication No. 2018-0134794.
[0133] In some embodiments, the binding protein is an antibody or antigen-binding fragment that binds to dimeric human MET (e.g., hMET.mFc) with a dissociation half-life (t½) greater than about 10 minutes when measured by surface plasmon resonance at 25°C or 37°C using a assay format or substantially similar assay as defined in Example 5 of U.S. Patent Publication No. 2018-0134794. According to a specific embodiment, the MET x MET bispecific antigen-binding protein useful herein binds to dimeric human MET for more than 10 minutes, more than 20 minutes, more than 30 minutes, more than 40 minutes, more than 50 minutes, more than 60 minutes, more than 70 minutes, more than 80 minutes, more than 90 minutes, more than 100 minutes, more than 200 minutes, more than 300 minutes, more than 400 minutes, more than 500 minutes, more than 60 minutes, more than 70 minutes, more than 80 minutes, more than 90 minutes, more than 100 minutes, more than 200 minutes, more than 300 minutes, more than 400 minutes, more than 500 minutes, more than 600 minutes, more than 700 minutes, or more than 800 minutes, more than 900 minutes, more than 1000 minutes, more than 1100 minutes, or more than t½ when measured by surface plasmon resonance using the assay format as defined in Example 5 of U.S. Patent Publication No. 2018-0134794.
[0134] In some embodiments, the binding protein is an antibody or its antigen-binding fragment, for example, a MET x MET bispecific antigen-binding protein that blocks the interaction between HGF and MET in an in vitro ligand binding assay. The MET x MET bispecific antigen-binding protein useful herein may block HGF binding to cells expressing human MET and may induce minimal or no MET activation in the absence of HGF signaling. For example, the MET x MET bispecific antigen-binding protein useful herein exhibits a certain degree of MET agonist activity in a cell-based MET activity reporter assay, such that the degree is less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, or less than 1% of the MET agonist activity observed in an equivalent activity reporter assay using a monospecific antibody containing only D1 or D2.
[0135] In one embodiment, the antibody or fragment thereof is a human monoclonal antibody or an antigen-binding fragment thereof that binds to MET, wherein the antibody or fragment thereof exhibits one or more of the following characteristics: (i) comprising an HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; (ii) comprising an LCVR having the amino acid sequence of SEQ ID NO. 138, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; (iii) an HCDR3 domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128 and 136, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity with respect thereto; and an LCDR3 domain comprising the amino acid sequence of SEQ ID NO. 144, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity with respect thereto; (iv) an amino acid sequence selected from the group consisting of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, and 132, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto, comprising an HCDR1 domain;HCDR2 domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, and 134, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; LCDR1 domain having the amino acid sequence of SEQ ID NO. 140, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; and LCDR2 domain having the amino acid sequence of SEQ ID NO. 142, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; (v) is a multispecific antigen-binding molecule comprising a first binding specificity for MET and a second binding specificity for a tumor-specific antigen; (vi) is a multispecific antigen-binding molecule comprising a first binding specificity for one epitope of MET and a second binding specificity for a second epitope of MET; (vii) 25; o C or 37 o When measured by surface plasmon resonance at C, K of less than approximately 230 nM D (viii) binds to the monomer human MET (e.g., hMET.mmh); (viii) K less than about 3 nM when measured by surface plasmon resonance at 25°C or 37°C. D (ix) binds to human MET; (x) blocks HGF from binding to MET; and (x) inhibits tumor growth and increases survival in subjects with cancer.
[0136] In one embodiment, the antibody or fragment thereof is a human monoclonal antibody or an antigen-binding fragment thereof that blocks HGF against MET, wherein the antibody or fragment thereof exhibits one or more of the following characteristics: (i) comprising an HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; (ii) comprising an LCVR having the amino acid sequence of SEQ ID NO. 138, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; (iii) an HCDR3 domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128 and 136, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity with respect thereto; and an LCDR3 domain comprising the amino acid sequence of SEQ ID NO. 144, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity with respect thereto; (iv) an amino acid sequence selected from the group consisting of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, and 132, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto, comprising an HCDR1 domain;HCDR2 domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, and 134, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; LCDR1 domain having the amino acid sequence of SEQ ID NO. 140, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; and LCDR2 domain having the amino acid sequence of SEQ ID NO. 142, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with respect thereto; (v) is a multispecific antigen-binding molecule comprising a first binding specificity for MET and a second binding specificity for a tumor-specific antigen; (vi) is a multispecific antigen-binding molecule comprising a first binding specificity for one epitope of MET and a second binding specificity for a second epitope of MET; (vii) 25; o C or 37 o When measured by surface plasmon resonance at C, K of less than approximately 230 nM D (viii) binds to the monomer human MET (e.g., hMET.mmh); (viii) K less than about 3 nM when measured by surface plasmon resonance at 25°C or 37°C. D (ix) binds to the dimeric human MET; and inhibits tumor growth and increases survival in subjects with cancer.
[0137] In certain embodiments, the binding protein is a MET x MET bispecific antibody or its antigen-binding fragment, wherein the first antigen-binding domain (D1) binds to the first epitope of human MET, and the second antigen-binding domain (D2) binds to the second epitope of human MET in its natural form, is recombinantly produced, or binds to its fragment. In some embodiments, D1 and D2 do not compete with each other to bind to human MET. In some embodiments, the binding protein exhibits minimal agonist activity in a cell-based MET activity reporter assay. In some embodiments, the bispecific antigen-binding molecule exhibits a degree of MET agonist activity in a cell-based MET activity reporter assay that is less than 10% of the MET agonist activity of a monovalent antigen-binding molecule containing D1 or D2 alone. In some embodiments, the bispecific antigen-binding molecule promotes the degradation of cell surface-expressed MET. In some embodiments, the bispecific antigen-binding molecule inhibits the growth of a tumor possessing a MET gene mutation or promotes tumor regression. In some embodiments, the bispecific antigen-binding molecule inhibits the growth of a tumor whose growth is induced by autocrine HGF signaling or promotes tumor regression.
[0138] In some embodiments, the anti-MET antibody or MET x MET bispecific antibody useful herein binds to an epitope or a portion of an epitope identical to any one of the exemplary specific antibodies described in Table 1 or Table 2 of the present invention, or to an antibody having the CDR sequence of any one of the exemplary antibodies described in Table 1 or Table 2. Likewise, a suitable binding protein also comprises an anti-MET antibody or MET x MET bispecific antibody that competes to bind to any one of the exemplary specific antibodies described in Table 1 or Table 2 of the present invention, or to an antibody having the CDR sequence of any one of the exemplary antibodies described in Table 1 or Table 2. For example, suitable binding proteins include an anti-MET antibody and a MET x MET bispecific antibody that cross-compete with one or more antibodies as defined in U.S. Patent Publication No. 2018-0134794 to bind to MET, or cross-compete with one or more antibodies as defined in U.S. Patent Publication No. 2018-0134794 to bind to MET.
[0139] The antibodies and antigen-binding fragments described herein specifically bind to MET to regulate the interaction between MET and HGF. MET x MET bispecific antibodies may bind to MET with high or low affinity. In certain embodiments, the antibody is a blocking antibody, wherein the antibody binds to MET and blocks the interaction between MET and HGF. In some embodiments, the blocking antibody of the present disclosure blocks the binding of HGF to MET. In some embodiments, the blocking antibody is useful for treating subjects suffering from cancer. They may be used to inhibit the growth of tumor cells in subjects. They may be used alone or as an adjuvant therapy in combination with other therapeutic moiety or method known in the art for treating cancer. In a specific embodiment, a MET x MET bispecific antibody that binds to MET with low affinity is used as a multispecific antigen-binding molecule, wherein the first binding specificity binds to MET with low affinity, and the second binding specificity binds to a different epitope of MET or a tumor-specific antigen.
[0140] Certain anti-MET antibodies and MET x MET bispecific antibodies of the present disclosure can bind to MET and neutralize its activity, as determined by in vitro or in vivo assays. The ability of the antibodies of the present disclosure to bind to MET and neutralize its activity can be measured using any standard method known to those skilled in the art, including binding assays or activity assays as described herein.
[0141] Non-limiting exemplary in vitro assays for measuring binding activity are exemplified in Examples 3 and 6 of US-2018-0134794 A1. In Example 6, the binding affinity and kinetic constants of a human MET x MET bispecific antibody against human MET were determined by surface plasmon resonance, and measurements were performed on a T200 Biacore device. In Example 7 of US-2018-0134794, a blocking assay was used to determine the ability of the anti-MET antibody and the MET x MET bispecific antibody to block the MET-binding ability of HGF. In Example 4 of US-2018-0134794, a blocking assay was used to determine cross-competition between different anti-MET antibodies. Example 8 of US-2018-0134794 describes the inhibition of growth of cells overexpressing MET by an anti-MET antibody and a MET x MET bispecific antibody. In Example 10 of US-2018-0134794, the MET x MET bispecific antibody was shown to induce MET degradation and inhibit both MET and ERK phosphorylation. US-2018-0134794 also provides several examples demonstrating tumor growth inhibition or tumor regression in both in vivo and in vitro induced by the MET x MET bispecific antibody.
[0142] Unless specifically stated otherwise, the term “antibody” as used herein should be understood to include an antibody molecule comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., “whole antibody molecule”) and their antigen-binding fragments. As used herein, terms such as “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, etc., include any natural, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the terms “antigen-binding fragment” of an antibody or “antibody fragment” refer to one or more fragments of an antibody that possess the ability to specifically bind to MET. Antibody fragments may include a Fab fragment, an F(ab’)2 fragment, an Fv fragment, a dAb fragment, a CDR-containing fragment, or an isolated CDR. In certain embodiments, the term “antigen-binding fragment” refers to a polypeptide of a multispecific antigen-binding molecule or a fragment thereof. In these embodiments, the term “antigen-binding fragment” comprises, for example, an extracellular domain of HFG that specifically binds to MET. The antigen-binding fragment of the antibody may be derived from the whole antibody molecule using any suitable standard technique, for example, proteolytic digestion or recombinant genetic engineering techniques including the manipulation and expression of DNA encoding an antibody variable domain and (optional) constant domain. Such DNA may be known and / or readily available from, for example, commercial sources, DNA libraries (including, for example, phage-antibody libraries), or synthesized. Such DNA may be sequenced and manipulated using chemical or molecular biological techniques, for example, to arrange one or more variable and / or constant domains into a suitable configuration, or to introduce codons, generate cysteine residues, modify, add, or delete amino acids, etc.
[0143] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) short-chain Fv(scFv) molecules; (vi) dAb fragments; and (vii) amino acid residues mimicking the hypervariable region of an antibody (e.g., the isolated complementarity determining region (CDR) such as the CDR3 peptide), or minimal recognition units composed of a restricted FR3-CDR3-FR4 peptide. Other engineered molecules, e.g., domain-specific antibodies, mono-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-transplant antibodies, diabodies, triabodidies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, divalent nanobodies, etc.), small modular immunotherapies (SMIPs), and shark variable IgNAR domains, etc. are also included in the expression "antigen-binding fragments" as used herein.
[0144] The antigen-binding fragment of an antibody generally contains at least one variable domain. This variable domain may have any size or amino acid composition and generally contains at least one CDR adjacent to or within the frame with one or more framework sequences. V L V combined with the domain H In an antigen-binding fragment having a domain, V H and V L Domains can be positioned relative to each other in any appropriate arrangement. For example, the variable domain is a dimer, V H - V H , V H - V L or V L - V L It may contain a dimer. Alternatively, the antigen-binding fragment of the antibody is monomer V H or V L It can include domains.
[0145] In a specific embodiment, the antigen-binding fragment of the antibody may comprise at least one variable domain covalently bonded to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within the antigen-binding fragment of the antibody of the present disclosure include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C LIn any configuration of variable and constant domains comprising any of the exemplary configurations listed above, such variable and constant domains may be directly connected to each other or connected by wholly or partially hinge or linker regions. A hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60, or more) amino acids resulting in a flexible or semi-flexible connection between adjacent variable and / or constant domains of a single polypeptide molecule. Additionally, the antigen-binding fragment of the antibody of the present disclosure may be a homo-dimer or hetero-dimer (or other multimer) of any one of the variable and constant domain configurations listed above (e.g., by disulfide bond(s)) to each other and / or one or more monomers V H or V L It can be included as a non-covalent combination with the domain.
[0146] As with complete antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies generally comprise at least two different variable domains, each of which may specifically bind to a separate antigen or specifically bind to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody format disclosed herein, may be suitable for use in the context of the antigen-binding fragment of the antibody disclosed herein using routine techniques available in the art.
[0147] The anti-MET antibodies and MET x MET bispecific antibodies and antibody fragments useful herein comprise proteins having amino acid sequences that differ from the amino acid sequences of the antibodies described herein but retain the ability to bind to MET. These variant antibodies and antibody fragments contain one or more additions, deletions, or substitutions of amino acids compared to the parental sequences, but exhibit biological activity substantially equivalent to that of the described antibodies. Likewise, the antibody-coding DNA sequences of the present disclosure comprise sequences encoding antibodies or antibody fragments that contain one or more additions, deletions, or substitutions of nucleotides compared to the disclosed sequences but are substantially biologically equivalent to the antibodies or antibody fragments of the present disclosure.
[0148] If two antigen-binding proteins or antibodies are pharmaceutical equivalents or pharmaceutical alternatives that do not show a significant difference in the rate and extent of absorption when administered, for example, at the same molar dose (single dose or multiple doses) under similar experimental conditions, they are considered biologically equivalent. If some antibodies are equivalent in extent of absorption but differ in the rate of absorption, they will be considered equivalents or pharmaceutical alternatives and may still be considered biologically equivalent, because this difference in the rate of absorption is intentional and reflected in the labeling, is not necessarily required to achieve an effective body drug concentration when used chronically, for example, and is considered not medically significant for a particular investigational drug.
[0149] In one embodiment, if two antigen-binding proteins have no clinically significant difference in safety, purity, or efficacy, they are bioequivalent.
[0150] In one embodiment, the subject may switch between the reference product and the biological product one or more times, and the two antigen-binding proteins are biologically equivalent if there is no expected increase in the risk of adverse events, including a clinically significant change in immunogenicity, or no decrease in efficacy compared to a continuous regimen without such switching.
[0151] In one embodiment, if both antigen-binding proteins act to the extent that such mechanisms are known by a common mechanism or common mechanism of action for the conditions of use(s), they are biologically equivalent.
[0152] Bioequivalence may be demonstrated by in vivo methods and / or in vitro methods. Measures of bioequivalence include, for example: (a) in vivo tests in humans or other mammals in which the concentration of an antibody or its metabolism is measured as a function of time in blood, plasma, serum, or other biological fluids; (b) in vitro tests associated with or capable of reasonably predicting human in vivo bioavailability data; (c) in vivo tests in humans or other mammals in which the appropriate acute pharmacological effect of the antibody (or its target) is measured as a function of time; and (d) well-controlled clinical trials to establish the safety, efficacy, or bioavailability or bioequivalence of the antibody.
[0153] Biologically equivalent variants of the antibody of the present disclosure may be constructed, for example, by making various substitutions of residues or sequences, or by deleting terminal or internal residues or sequences that are not necessary for biological activity. For example, by deleting or substituting cysteine residues essential for biological activity with other amino acids, the formation of unnecessary or incorrect intramolecular disulfide bridges upon denaturation may be prevented. In another context, biologically equivalent antibodies may include antibody variants comprising amino acid changes that alter the glycosylation properties of the antibody, for example, mutations that remove or eliminate glycosylation.
[0154] The anti-MET antibodies and MET x MET bispecific antibodies useful herein may comprise an Fc domain containing one or more mutations that enhance or attenuate antibody binding to the FcRn receptor, for example, at acidic pH compared to neutral pH. For example, the present disclosure describes C of the Fc domain H 2 or C HMET x MET bispecific antibodies comprising mutations in three regions, wherein the mutation(s) increase the affinity of the Fc domain for FcRn in an acidic environment (e.g., in endosomes with a pH in the range of about 5.5 to 6.0). Such mutations may increase the serum half-life of the antibody when administered to animals. Non-limiting examples of such Fc modifications include, for example, modifications at position 250 (e.g., E or Q); modifications at positions 250 and 428 (e.g., L or F); modifications at position 252 (e.g., L / Y / F / W or T), position 254 (e.g., S or T), and position 256 (e.g., S / R / Q / E / D or T); or variations at position 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or position 434 (e.g., A, W, H, F or Y[N434A, N434W, N434H, N434F or N434Y]); or variations at position 250 and / or 428; or variations at position 307 or 308 (e.g., 308F, V308F) and position 434. In one embodiment, the variations include 428L (e.g., M428L) and 434S (e.g., N434S) variations; 428L, 259I (e.g., V259I), and 308F (e.g., V308F) variations; Variants of 433K (e.g., H433K) and 434 (e.g., 434Y); variants of 252, 254, and 256 (e.g., 252Y, 254T, and 256E); variants of 250Q and 428L (e.g., T250Q and M428L); and variants of 307 and / or 308 (e.g., 308F or 308P). In another embodiment, the variants include variants of 265A (e.g., D265A) and / or 297A (e.g., N297A).
[0155] For example, useful herein are anti-MET antibodies and MET x MET bispecific antibodies comprising an Fc domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 376V and 434H (e.g., D376V and N434H); 307A, 380A, and 434A (e.g., T307A, E380A, and N434A); and 433K and 434F (e.g., H433K and N434F). In one embodiment, the present disclosure comprises a MET x MET bispecific antibody comprising an Fc domain containing an S108P mutation in the hinge region of IgG4 to promote dimer stabilization. All possible combinations of the aforementioned Fc domain mutation and other mutations within the antibody variable domain provided in Table 1 of the present invention are considered to be within the scope of the present disclosure.
[0156] The anti-MET antibody and MET x MET bispecific antibody useful in this invention exhibit chimeric heavy chain invariance (C H It may include a ) region, where Chimera C H The region is one or more immunoglobulin isoforms C H It includes segments derived from the region. For example, the antibody contains C derived from human IgG1, human IgG2, or human IgG4 molecules. H C derived from human IgG1, human IgG2, or human IgG4 molecules in combination with some or all of the 3 domains H 2. Chimera C containing part or all of the domain HIt may include a region. According to a specific embodiment, the antibody is a chimeric C having a chimeric hinge region. H It includes a region. For example, the chimeric hinge may include an "upper hinge" amino acid sequence (amino acid residues at positions 216 to 227 according to EU numbering) derived from a human IgG1, human IgG2, or human IgG4 hinge region combined with a "lower hinge" sequence (amino acid residues at positions 228 to 236 according to EU numbering) derived from a human IgG1, human IgG2, or human IgG4 hinge region. According to a specific embodiment, the chimeric hinge region includes amino acid residues derived from the human IgG1 or human IgG4 upper hinge and amino acid residues derived from the human IgG2 lower hinge. Chimeric C as described herein H An antibody comprising a region may, in certain embodiments, exhibit a modified Fc effector function without adversely affecting the therapeutic or pharmacokinetic properties of the antibody. (See, for example, USSN No. 14 / 170,166 filed January 31, 2014 (the entire disclosure thereof is incorporated herein by reference)).
[0157] B. Positron Emitter and Chelation Moiety
[0158] Suitable positron emitters include, but are not limited to, those that form a stable complex with a chelation moiety and have a physical half-life suitable for immuno-PET imaging purposes. Exemplary positron emitters are 89 Zr, 68 Ga, 64 Cu, 44 Sc, and 86 Includes, but is not limited to, Y. Suitable positron emitters are those that bind directly to MET-binding proteins ( 76 Br and 124 Including but not limited to I), and those introduced through a prosthetic group (e.g., 18It also includes F).
[0159] The chelating moiety described herein is a chemical moiety that is covalently bound to a MET-binding protein (e.g., a MET x MET bispecific antibody) and comprises a portion capable of chelating a positron emitter (i.e., capable of reacting with the positron emitter to form a regulated chelate complex). Suitable moietyes include those that enable the efficient addition of a specific metal and form a metal-chelator complex that is sufficiently stable in vivo for diagnostic use (e.g., immuno-PET imaging). Exemplary chelating moietyes include those that minimize the dissociation of the positron emitter and the accumulation of minerals in bone, plasma proteins, and / or bone marrow deposition to a degree suitable for diagnostic use.
[0160] Examples of chelation moiety include positron emitters 89 Zr, 68 Ga, 64 Cu, 44 Sc, and / or 86 It includes, but is not limited to, those that form stable complexes with Y. An exemplary chelation moiety is, Nature Protocols , 5(4): 739, 2010; Bioconjugate Chem ., 26(12): 2579 (2015); Chem Commun (Camb ), 51(12): 2301 (2015); Mol. Pharmaceutics , 12: 2142 (2015); Mol. Imaging Biol ., 18: 344 (2015); Eur. J. Nucl. Med. Mol. Imaging , 37:250 (2010); Eur. J. Nucl. Med. Mol. Imaging (2016). doi:10.1007 / s00259-016-3499-x; Bioconjugate Chem., 26(12): 2579 (2015); WO 2015 / 140212A1; and US No. 5,639,879, including but not limited to those described therein (these documents are incorporated herein by reference in their entirety).
[0161] Exemplary chelation moiety is also desperioxamine (DFO, also known as deferoxamine), 1,4,7,10-tetraacetic acid (DOTA), diethylenetriaminepentaacetic acid (DTPA), ethylenediaminetetraacetic acid (EDTA), (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphon)acid (DOTP), 1R, 4R, 7R, 10R)-α'α''α''-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTMA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), H4 octapa, H6 phosphapa, H2 depapa, H5 decapapa, H2 azapa, HOPO, DO2A, 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM), 1,4,7-triazcyclononan-N,N',N''-triacetic acid (NOTA), 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM), 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-acetoacetic acid (CB-TE2A), 1,4,7,10-tetraazacyclododecane (Cyclen), 1,4,8,11-tetraazacyclotetradecane (Cyclam), octadentate chelator, hexadentate chelator, phosphonate-series chelator, Macrocyclic chelators, chelators comprising macrocyclic terephthalamide ligands, bifunctional chelators, fusarinin C and fusarinin C derivative chelators, triacetylfusarinin C (TAFC), perioxamine E (FOXE), perioxamine B (FOXB), ferrichrome A (FCHA), etc., are included but not limited thereto.
[0162] In some embodiments, the chelating moiety is covalently bound to a MET-binding protein (e.g., an antibody or its antigen-binding fragment) through a linker moiety that covalently attaches the chelating portion of the chelating moiety to the binding protein. In some embodiments, these linker moietyes are formed from a reaction between a reactive moiety of the MET-binding protein (e.g., cysteine or lysine of the antibody) and a reactive moiety attached to the chelator (e.g., including a p-isothiocyanatobenzyl group and a reactive moiety provided in the conjugation method below). Additionally, these linker moietyes optionally include a chemical group used to control polarity, solubility, steric interaction, stiffness, and / or the length between the chelating portion and the MET-binding protein.
[0163] C. Preparation of Radiolabeled MET-binding protein conjugates
[0164] A radiolabeled anti-MET antibody or MET x MET bispecific antibody conjugate can be prepared by (1) reacting a molecule comprising a positron emitter chelator and a moiety that reacts with a desired junction site of the MET binding protein with a MET binding protein (e.g., a MET x MET bispecific antibody), and (2) loading a desired positron emitter.
[0165] Suitable conjugation sites include, but are not limited to, lysine and cysteine, all of which may be, for example, natural or engineered, and may be, for example, present in the heavy or light chain of the antibody. Cysteine conjugation sites include, but are not limited to, those obtained by mutation, insertion, or reduction of antibody disulfide bonds. Methods for making cysteine-engineered antibodies include, but are not limited to, those disclosed in WO2011 / 056983. Site-specific conjugation methods may be used to induce a conjugation reaction at a specific site of the antibody to achieve a desired stoichiometry and / or a desired drug-to-antibody (DAR) ratio. Such conjugation methods, including but not limited to glutamine conjugation, Q295 conjugation, and transglutaaminase-mediated conjugation, are known to those skilled in the art, including cysteine engineering, enzymatic methods, and chemical-enzymatic methods, J.Clin.Immunol Includes, but not limited to, those described in ., 36: 100 (2016) (the whole of which is incorporated herein by reference). A suitable moiety that responds to the desired conjugation site generally enables efficient and easy binding of MET-binding proteins (e.g., antibodies and positron emitter chelators). Reactive moiety for the lysine and cysteine sites comprises an electrophilic group known to those skilled in the art. In certain embodiments, where the desired conjugation site is lysine, the reactive moiety is an isothiocyanate, e.g., a p-isothiocyanatobenzyl group, or a reactive ester. In certain embodiments, where the desired conjugation site is cysteine, the reactive moiety is a maleimide.
[0166] When the chelator is desperioxamine (DFO, also known as deferoxamine), the appropriate reactive moiety is an isothiocyanatobenzyl group, n-hydroxysuccinimide ester, 2,3,5,6-tetrafluorophenol ester, n-succinimidyl- S-Acetylthioacetate, and BioMed Research International ..., Vol 2014, Article ID 203601 (the entirety of which is incorporated herein by reference) includes, but is not limited to, those described therein. In certain embodiments, the MET binding protein is an antibody, and the molecule comprising a positron emitter chelator and a moiety reactive to the binding site is p-isothiocyanatobenzyl-desperioxamine (p-SCN-Bn-DFO):
[0167] .
[0168] The addition of a positron emitter is achieved by incubating a MET-coupled protein chelator conjugate having a positron emitter for a sufficient time to allow the positron emitter to be tuned to the chelator, for example, by performing the method described in the embodiments provided herein or a substantially similar method.
[0169] D. Exemplary embodiment of the composite
[0170] The present disclosure includes a radiolabeled antibody conjugate comprising an antibody or an antigen-binding fragment thereof that binds to human MET, e.g., an anti-MET antibody or a MET x MET bispecific antibody, and a positron emitter. Additionally, the present disclosure includes a radiolabeled antibody conjugate comprising an anti-MET antibody or a MET x MET bispecific antibody, a chelating moiety, and a positron emitter.
[0171] In some embodiments, the chelation moiety is 89 It includes a chelator capable of forming a complex with Zr. In a specific embodiment, the chelating moiety includes desperioxamine. In a specific embodiment, the chelating moiety is p-isothiocyanatobenzyl-desperioxamine.
[0172] In some embodiments, the positron emitter 89Zr. In some embodiments, less than 1.0% of the MET binding protein is conjugated to a positron emitter, less than 0.9% of the MET binding protein is conjugated to a positron emitter, less than 0.8% of the MET binding protein is conjugated to a positron emitter, less than 0.7% of the MET binding protein is conjugated to a positron emitter, less than 0.6% of the MET binding protein is conjugated to a positron emitter, less than 0.5% of the MET binding protein is conjugated to a positron emitter, less than 0.4% of the MET binding protein is conjugated to a positron emitter, less than 0.3% of the MET binding protein is conjugated to a positron emitter, less than 0.2% of the MET binding protein is conjugated to a positron emitter, or less than 0.1% of the MET binding protein is conjugated to a positron emitter.
[0173] In some embodiments, the ratio of the chelating moiety to the antibody of the conjugate is 1 to 2. As used herein, the “chelating moiety to antibody ratio” is the average ratio of the chelator moiety to the antibody and is a measure of the amount of chelator added per antibody. This ratio is similar to the “DAR,” i.e., the drug-antibody ratio, used by those skilled in the art to measure the amount of drug added per antibody for antibody-drug conjugates (ADCs); in the context of the iPET imaging conjugates described herein, the chelating moiety to antibody ratio is the same as the method described herein or other DAR determination methods known in the art, e.g., Wang et al., Antibody-Drug Conjugates, The 21 st This can be verified using the methods described in Century Magic Bullets for Cancer (2015). In some embodiments, the ratio of chelated moiety to antibody is 1.0 to 4.0, or about 1.0 to 3.0, or about 1.0 to 2.0. In some embodiments, the ratio of chelated moiety to antibody is about 1.26, e.g., about 1.3.
[0174] In a specific embodiment, the chelation moiety is p-isothiocyanatobenzyl-desperioxamine and the positron emitter is 89 It is Zr. In another specific embodiment, the chelation moiety is p-isothiocyanatobenzyl-desperioxamine and the positron emitter is 89 It is Zr, and the ratio of the chelation moiety to the antibody of the conjugate is 1 to 2.
[0175] In some embodiments, an antigen-binding protein that binds to MET is provided herein, wherein the antigen-binding protein that binds to MET described above is covalently bonded to one or more moieties having the following structure:
[0176] -LM Z
[0177] (wherein L is a chelation moiety; M is a positron emitter; z is independently 0 or 1 in each case; and at least one of z is 1).
[0178] In a specific embodiment, the radiolabeled antigen-binding protein is a compound of formula (I):
[0179] MLA-[LM Z ] k
[0180] Chemical formula (I)
[0181] (In the formula, A is a protein that binds to MET; L is a chelating moiety; M is a positron emitter; z is 0 or 1; and k is an integer from 0 to 30. In some embodiments, k is 1. In some embodiments, k is 2).
[0182] In some implementations, L is as follows:
[0183] .
[0184] In some embodiments, M is 89 It is Zr.
[0185] In some embodiments, k is an integer from 1 to 2. In some embodiments, k is 1. In some embodiments, k is 2.
[0186] In some implementations, -LM is as follows:
[0187] .
[0188] also, 89 A method for synthesizing a radiolabeled antibody conjugate comprising the step of contacting a compound of formula (III) having Zr is included in the present disclosure:
[0189]
[0190] (In the formula, A is an antibody that binds to MET or its antigen-binding fragment).
[0191] In a specific embodiment, the compound of formula (III) is synthesized by the step of contacting an antibody that binds to MET or its antigen-binding fragment with p-SCN-Bn-DFO.
[0192] Compound of chemical formula (III) and 89 The reaction product between Zr is also provided herein.
[0193] Additionally, a compound of formula (III) is provided herein:
[0194]
[0195] (In the formula, A is an antibody that binds to MET or an antigen-binding fragment thereof, and k is an integer from 1 to 30. In some embodiments, k is 1 or 2).
[0196] (i) an antibody or its antigen-binding fragment that binds to MET, and (ii) an antibody conjugate comprising one or more chelating moieties is provided herein.
[0197] In some embodiments, the chelating moiety includes the following:
[0198]
[0199] It is a covalent bond to an antibody or its antigen-binding fragment.
[0200] In some embodiments, the antibody conjugate has a chelation moiety-to-antibody ratio of about 1.0 to about 2.0. In some embodiments, the antibody conjugate has a chelation moiety-to-antibody ratio of about 1.3.
[0201] In some embodiments, a composition comprising a composite having the following structure is provided herein:
[0202] AL k
[0203] (In the formula, A is a protein that binds to MET; L is a chelation moiety; k is an integer from 1 to 30; and the conjugate is chelated by a positron emitter in an amount sufficient to provide specific activity suitable for clinical PET imaging). In some embodiments, the amount of chelated positron emitter is sufficient to provide specific activity of about 1 to about 50 mCi per 1 to 50 mg of protein that binds to MET.
[0204] In some embodiments, the amount of chelated positron emitter is sufficient to provide specific activity of up to 25 mCi, up to 20 mCi, up to 15 mCi, up to 12 mCi, or up to 10 mCi per 1 to 50 mg of protein binding to MET, for example, about 3 to about 25 mCi, about 10 to about 25 mCi, about 1 to about 15 mCi, about 3 to about 15 mCi, about 5 to about 25 mCi, or about 15 to about 25 mCi, or in the range of about 3 to about 10 mCi, or about 12 mCi, or about 21 mCi.
[0205] In some embodiments, the antibody or its antigen-binding fragment has a binding dissociation equilibrium constant (K) of less than about 230 nM when measured by surface plasmon resonance analysis at 25°C or 37°C. D) binds to the monomer human MET.
[0206] In some embodiments, the antibody or its antigen-binding fragment has a K of less than about 3 nM in surface plasmon resonance analysis at 25°C or 37°C. D It binds to the dimeric human MET.
[0207] In some embodiments, the antibody or its antigen-binding fragment competes with a reference antibody comprising the complementarity determining region (CDR) of HCVR and the CDR of LCVR to bind to human MET, wherein HCVR has an amino acid sequence selected from the group consisting of HCVR sequences listed in Table 1, and LCVR has an amino acid sequence shown in Table 1. In some embodiments, the reference antibody or its antigen-binding fragment comprises an HCVR / LCVR amino acid sequence pair as presented in Table 1. In some embodiments, the reference antibody comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs 2 / 138, 10 / 138, 18 / 138, 26 / 138, 34 / 138, 42 / 138, 50 / 138, 58 / 138, 66 / 138, 74 / 138, 82 / 138, 90 / 138, 98 / 138, 106 / 138, 114 / 138, 122 / 138, and 130 / 138.
[0208] In certain embodiments, the antibody or its antigen-binding fragment blocks HGF binding to MET. In some embodiments, the antibody or its antigen-binding fragment does not increase or decrease MET binding to its ligand.
[0209] In some embodiments, the antibody or its antigen-binding fragment comprises a complementarity determining region (CDR) of HCVR and a CDR of LCVR, wherein HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122 and 130, and LCVR has the amino acid sequence of SEQ ID NO. 138. In a specific embodiment, the isolated antibody comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs 2 / 138, 10 / 138, 18 / 138, 26 / 138, 34 / 138, 42 / 138, 50 / 138, 58 / 138, 66 / 138, 74 / 138, 82 / 138, 90 / 138, 98 / 138, 106 / 138, 114 / 138, 122 / 138, and 130 / 138.
[0210] In some embodiments, the antibody is a human monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human MET, wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of HCVR sequences listed in Table 1.
[0211] In some embodiments, the antibody is a human monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human MET, wherein the antibody or the antigen-binding fragment thereof comprises a light chain variable region (LCVR) having the amino acid sequence shown in Table 1.
[0212] In some embodiments, the antibody is a human monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human MET, wherein the antibody or the antigen-binding fragment thereof comprises (a) an HCVR having an amino acid sequence selected from the group consisting of HCVR sequences listed in Table 1; and (b) an LCVR having an amino acid sequence shown in Table 1.
[0213] In some embodiments, the antibody or its antigen-binding fragment comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within any one of the heavy chain variable regions (HCVR) listed in Table 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within the light chain variable region (LCVR) shown in Table 1.
[0214] In some embodiments, the antibody or antigen-binding fragment comprises the following:
[0215] (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, and 132;
[0216] (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of sequence numbers 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, and 134;
[0217] (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of sequence numbers 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128 and 136;
[0218] (d) LCDR1 domain having the amino acid sequence of SEQ ID NO. 140;
[0219] (e) an LCDR2 domain having the amino acid sequence of SEQ ID NO. 142; and
[0220] (f) LCDR3 domain having the amino acid sequence of SEQ ID NO. 144.
[0221] In some embodiments, the antibody or antibody binding fragment comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs 2 / 138, 10 / 138, 18 / 138, 26 / 138, 34 / 138, 42 / 138, 50 / 138, 58 / 138, 66 / 138, 74 / 138, 82 / 138, 90 / 138, 98 / 138, 106 / 138, 114 / 138, 122 / 138, and 130 / 138.
[0222] In some embodiments, the antibody or its antigen-binding fragment comprises a CDR of HCVR and a CDR of LCVR, wherein HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122 and 130, and LCVR has the amino acid sequence of SEQ ID NO. 138.
[0223] In some embodiments, the antibody or its antigen-binding fragment is an anti-MET antibody containing a CDR within the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 82 / 138. In some embodiments, the antibody or its antigen-binding fragment is an anti-MET antibody containing the HCVR amino acid sequence of SEQ ID NO. 82 and the LCVR amino acid sequence of SEQ ID NO. 138.
[0224] In some embodiments, the antibody or its antigen-binding fragment is an anti-MET antibody containing a CDR within the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 18 / 138. In some embodiments, the antibody or its antigen-binding fragment is an anti-MET antibody containing the HCVR amino acid sequence of SEQ ID NO. 18 and the LCVR amino acid sequence of SEQ ID NO. 138.
[0225] In some embodiments, the antibody or its antigen-binding fragment is an anti-MET antibody containing a CDR within the HCVR / LCVR amino acid sequence pair of SEQ ID NO. 58 / 138. In some embodiments, the antibody or its antigen-binding fragment is an anti-MET antibody containing the HCVR amino acid sequence of SEQ ID NO. 58 and the LCVR amino acid sequence of SEQ ID NO. 138.
[0226] In some embodiments, the antibody or its antigen-binding fragment is a MET x MET bispecific antigen-binding protein comprising a CDR in the D1-HCVR amino acid sequence of SEQ ID NO. 58 and a CDR in the D2-HCVR amino acid sequence of SEQ ID NO. 82. In some embodiments, the MET x MET bispecific antigen-binding protein further comprises a CDR in the LCVR amino acid sequence of SEQ ID NO. 138. In some embodiments, the antibody or its antigen-binding fragment is a MET x MET bispecific antigen-binding protein comprising the D1-HCVR amino acid sequence of SEQ ID NO. 58 and the D2-HCVR amino acid sequence of SEQ ID NO. 82. In some embodiments, the MET x MET bispecific antigen-binding protein further comprises the LCVR amino acid sequence of SEQ ID NO. 138.
[0227] In some embodiments, the antibody or its antigen-binding fragment is a MET x MET bispecific antigen-binding protein comprising a CDR in the D1-HCVR amino acid sequence of SEQ ID NO. 18 and a CDR in the D2-HCVR amino acid sequence of SEQ ID NO. 82. In some embodiments, the MET x MET bispecific antigen-binding protein further comprises a CDR in the LCVR amino acid sequence of SEQ ID NO. 138. In some embodiments, the antibody or its antigen-binding fragment is a MET x MET bispecific antigen-binding protein comprising the D1-HCVR amino acid sequence of SEQ ID NO. 18 and the D2-HCVR amino acid sequence of SEQ ID NO. 82.
[0228] In some embodiments, the radiolabeled antibody conjugate comprises an antibody that binds to MET or an antigen-binding fragment thereof, a chelating moiety, and a positron emitter, wherein the antibody that binds to MET or an antigen-binding fragment thereof comprises a CDR in the D1-HCVR amino acid sequence of SEQ ID NO. 58, a CDR in the D2-HCVR amino acid sequence of SEQ ID NO. 82, and a CDR in the LCVR amino acid sequence of SEQ ID NO. 138, the chelating moiety is desperioxamine, and the positron emitter 89 It is Zr.
[0229] In some embodiments, the radiolabeled antibody conjugate comprises an antibody that binds to MET or an antigen-binding fragment thereof, a chelating moiety, and a positron emitter, wherein the antibody that binds to MET or an antigen-binding fragment thereof comprises the D1-HCVR amino acid sequence of SEQ ID NO. 58, the D2-HCVR amino acid sequence of SEQ ID NO. 82, and the LCVR amino acid sequence of SEQ ID NO. 138, the chelating moiety is desperioxamine, and the positron emitter 89 It is Zr.
[0230] III. Method using radiolabeled immunoconjugates
[0231] In certain embodiments, the present disclosure provides a method for the diagnostic and therapeutic use of the radiolabeled antibody conjugate of the present disclosure.
[0232] According to one embodiment, the present disclosure provides a method for detecting MET in a tissue, the method comprising the steps of: administering a radiolabeled antibody conjugate provided herein to the tissue; and visualizing MET expression by positron emission tomography (PET) imaging. In a specific embodiment, the tissue comprises a cell or cell line. In a specific embodiment, the tissue is present within a subject, and the subject is a mammal. In a specific embodiment, the subject is a non-human subject. In a specific embodiment, the subject has cancer.
[0233] According to one embodiment, the present disclosure provides a method for imaging tissue expressing MET, the method comprising the steps of: administering a radiolabeled antibody conjugate of the present disclosure to the tissue; and visualizing MET expression by positron emission tomography (PET) imaging. In one embodiment, the tissue comprises a tumor. In one embodiment, the tissue comprises a tumor cell culture or a tumor cell line. In one embodiment, the tissue comprises a tumor lesion of a subject.
[0234] According to one embodiment, the present disclosure provides a method for measuring a response to anti-MET therapy in a subject having cancer, wherein the response to therapy is measured by a change in MET expression relative to MET expression prior to therapy. The method according to the present embodiment comprises the steps of administering a radiolabeled antibody conjugate provided herein to a subject in need thereof, and visualizing MET expression by positron emission tomography (PET) imaging. A decrease in MET expression relative to MET expression prior to therapy is correlated with a positive response to anti-MET therapy.
[0235] According to one embodiment, the present disclosure provides a method for determining whether a subject having a solid tumor is suitable for an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway, the method comprising the steps of administering a radiolabeled antibody conjugate of the present disclosure to a subject and localizing the administered radiolabeled antibody conjugate within the tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present in the tumor, the subject is identified as suitable for an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway.
[0236] A useful anti-tumor therapy according to the method disclosed herein may be any therapeutically useful inhibitor of the HGF / MET signaling pathway, namely an inhibitor of HGF, an inhibitor of MET, or an inhibitor of EKR, or any other downstream protein within the HGF / MET signaling pathway. In some embodiments, the anti-tumor therapy comprises an anti-MET antibody or an antigen-binding fragment thereof, e.g., any one or more of the antibodies listed in Table 1. In some embodiments, the anti-tumor therapy comprises any one or more MET x MET bispecific antibodies, e.g., any one of the bispecific antibodies listed in Table 2. In some embodiments, the antibody, bispecific antibody, or antigen-binding fragment thereof is conjugated to a drug useful for treating cancer (i.e., an ADC). An exemplary anti-MET ADC is disclosed in US-2018-0134794 A1.
[0237] According to one aspect, the present disclosure provides a method for identifying a candidate subject for an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway, the method comprising the steps of administering a radiolabeled antibody conjugate of the present disclosure to a subject having a tumor, and localizing the administered radiolabeled antibody conjugate within the tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present in the tumor, the subject is identified as suitable for an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway.
[0238] According to one aspect, the present disclosure provides a method for predicting the response of a subject to anti-tumor therapy, the method comprising the step of determining whether a tumor is MET-positive, wherein if the tumor is MET-positive, the response of the subject to anti-tumor therapy is predicted to be positive. In a specific embodiment, the tumor is determined to be positive by administering the radiolabeled antibody conjugate of the present disclosure and localizing the radiolabeled antibody conjugate within the tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present within the tumor, the tumor is indicated to be MET-positive.
[0239] According to one aspect, the present disclosure provides a method for predicting the response of a subject having a solid tumor to anti-tumor therapy, the method comprising the step of determining whether the tumor is MET-positive, wherein if the tumor is MET-positive, the response of the subject is predicted to be positive. In a specific embodiment, the tumor is determined to be positive by administering the radiolabeled antibody conjugate of the present disclosure and localizing the radiolabeled antibody conjugate within the tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present within the tumor, the tumor is MET-positive.
[0240] According to one embodiment, the present disclosure provides a method for detecting a MET-positive tumor in a subject. According to the present embodiment, the method comprises the steps of administering a radiolabeled antibody conjugate of the present disclosure to a subject; and localizing the radiolabeled antibody conjugate within a tumor by PET imaging, wherein if the radiolabeled antibody conjugate is present within the tumor, the tumor is MET-positive. In some embodiments, the detection method identifies the location of the tumor. In some embodiments, the detection method enables monitoring the progress of anti-tumor therapy, such as whether the tumor regresses or stops growing.
[0241] According to one embodiment, the present disclosure provides a method for determining the size of a MET-positive tumor in a subject. According to the present embodiment, the method comprises the steps of administering a radiolabeled antibody conjugate of the present disclosure to a subject; and visualizing the radiolabeled antibody conjugate by PET imaging, wherein the size of the tumor may be determined.
[0242] A method for determining the presence of MET-expressing cells in a subject is also provided herein. The method comprises the steps of administering the radiolabeled anti-MET antibody conjugate or MET x MET bispecific antibody conjugate described herein to a subject and visualizing MET expression by PET imaging.
[0243] A method for diagnosing and treating a subject having a tumor is provided herein, the method comprising the steps of: administering a radiolabeled conjugate described herein to a subject, imaging the localization of the radiolabeled antibody conjugate via PET imaging to determine whether the tumor is MET-positive; diagnosing the subject as having a MET-positive tumor; and administering an anti-tumor therapy comprising an inhibitor of the HGF / MET signaling pathway to the subject.
[0244] A method for diagnosing a subject having a MET-expressing tumor is provided herein, comprising the steps of: administering a radiolabeled anti-MET antibody conjugate or a MET x MET bispecific antibody conjugate described herein to a subject; visualizing MET expression by PET imaging; and diagnosing the subject as a MET-expressing tumor when MET expression is visualized by PET imaging.
[0245] As used herein, the term “subject in need” means a human or non-human mammal exhibiting one or more symptoms or signs of cancer, and / or a human or non-human mammal diagnosed with cancer (including solid tumors) and requiring treatment for it. In many embodiments, the term “subject” may be used interchangeably with the term “patient.” For example, a human subject may be diagnosed with a primary tumor or metastatic tumor and / or diagnosed with one or more symptoms or signs including unexplained weight loss, weakness, chronic fatigue, loss of appetite, fever, night sweats, bone pain, shortness of breath, abdominal distension, chest pain / thoracic pressure, splenic distension, and elevated levels of cancer-related biomarkers (e.g., CA125). The foregoing term includes a subject having a primary tumor or an established tumor. In certain embodiments, the foregoing expression includes human subjects having or having solid tumors such as colorectal cancer, breast cancer, lung cancer, prostate cancer, skin cancer, liver cancer, bone cancer, ovarian cancer, cervical cancer, pancreatic cancer, head and neck cancer, and brain cancer, or requiring treatment for such tumors. The term includes subjects having primary tumors or metastatic tumors (malignant tumors of advanced stage). In certain embodiments, the expression “subjects requiring this” includes patients having tumors that are resistant or refractory to prior therapy (e.g., treatment using anticancer agents) or solid tumors that are not adequately controlled by prior therapy. For example, the foregoing expression includes subjects who have received one or more treatments with prior therapy, such as chemotherapy (e.g., carboplatin or docetaxel). In certain embodiments, the expression “subjects requiring this” includes patients having solid tumors that have been treated with one or more prior therapies but subsequently relapsed or metastasized.
[0246] In certain embodiments, the method of the present disclosure is used in an object having a solid tumor. The terms “tumor,” “cancer,” and “malignant tumor” are used interchangeably herein. As used herein, the term “solid tumor” generally refers to an abnormal mass of tissue that does not contain a cyst or a fluid region. A solid tumor may be benign (not cancerous) or malignant (cancer). For the purposes of the present disclosure, the term “solid tumor” means a malignant solid tumor. The foregoing term includes different types of solid tumors named according to the type of cells forming the solid tumor, namely, sarcoma, carcinoma, and lymphoma. In certain embodiments, the term “solid tumor” includes, but is not limited to, colorectal cancer, ovarian cancer, prostate cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colorectal cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, kidney cancer, stomach cancer, esophageal cancer, head and neck cancer, salivary gland cancer, and multiple myeloma.
[0247] In some embodiments, the tumor is selected from the group consisting of acute myeloid leukemia, adult T-cell leukemia, astrocytoma, cholangiocarcinoma, chronic myeloid leukemia, gastric cancer (e.g., gastric cancer with MET amplification), glioblastoma, head and neck cancer (e.g., head and neck squamous cell carcinoma [HNSCC]), Kaposi sarcoma, leiomyosarcoma, lung cancer (e.g., non-small cell lung cancer [NSCLC]), lymphoma, malignant glioma, malignant mesothelioma, melanoma, mesothelioma, malignant fibrous histiocytoma (MFH), fibrosarcoma, multiple myeloma, nasopharyngeal carcinoma, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, synovial sarcoma, thyroid cancer, and Wilms tumor.
[0248] According to one embodiment, the present disclosure provides a method for treating a tumor in a subject. The method according to the present embodiment comprises the steps of determining whether the tumor is MET-positive; and administering one or more doses of an inhibitor of the HGF / MET signaling pathway. In some embodiments, the inhibitor is an anti-MET antibody, a MET x MET bispecific antibody, or a drug conjugate thereof. In certain embodiments, the tumor is determined to be MET-positive by the steps of administering the radiolabeled antibody conjugate of the present disclosure to a subject; and visualizing the radiolabeled antibody conjugate in the tumor by PET imaging. The presence of the radiolabeled antibody conjugate in the tumor indicates that the tumor is MET-positive. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is non-small cell lung cancer. In some embodiments, the cancer is gastric cancer.
[0249] As used herein, the term "treatment" (treat, treating, etc.) means alleviating symptoms, eliminating the cause of symptoms in a temporary or permanent manner, delaying or inhibiting tumor growth, reducing tumor cell load or tumor burden, promoting tumor regression, inducing tumor shrinkage, necrosis and / or removal, preventing tumor recurrence, preventing or inhibiting metastasis, inhibiting metastatic tumor growth and / or extending the subject's survival time.
[0250] According to one aspect, the present disclosure provides a method for monitoring the efficacy of an anti-tumor therapy in a subject undergoing cancer treatment, the method comprising: administering a radiolabeled antibody conjugate of the present disclosure to a subject; imaging the localization of the administered radiolabeled conjugate within the tumor by PET imaging; and determining tumor growth, wherein a decrease in the radiolabeled signal relative to baseline indicates tumor regression and the efficacy of the anti-tumor therapy. In a specific embodiment, the anti-tumor therapy comprises an inhibitor of the HGF / MET signaling pathway (e.g., a MET x MET bispecific antibody).
[0251] As used herein, the term “baseline” for MET expression in a tumor refers to the level of radiolabeled conjugate absorbed by the subject before or at the time of administration of the dose of anti-tumor therapy. The absorption of the radiolabeled conjugate is determined using methods known in the art (see, e.g., Oosting et al., 2015, J. Nucl. Med. 56: 63-69). In certain embodiments, the anti-tumor therapy comprises an HGF / MET signaling pathway inhibitor.
[0252] To determine whether tumor regression is present, the uptake of a radiolabeled conjugate is an inhibitor of the HGF / MET signaling pathway (e.g., After administration of the MET x MET bispecific antibody), it is quantified at baseline and at one or more time points. For example, the uptake of the administered radiolabeled antibody conjugate (e.g., radiolabeled MET x MET bispecific antibody conjugate) is measured on days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 22, 25, 29, 36, 43, 50, 57, 64, 71, and 85 following initial treatment with an inhibitor of the HGF / MET signaling pathway (e.g., MET x MET bispecific antibody); It may be measured at time points after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 weeks or more. The difference between the uptake value at a specific time point after the initiation of treatment and the uptake value at baseline is used to establish whether there was a difference in the amount of tumor tissue (tumor regression or progression). For example, upon treatment with at least a single dose of an inhibitor of the HGF / MET signaling pathway, a decrease in uptake relative to baseline implies tumor regression, which indicates the efficacy of the anti-tumor therapy.
[0253] In a specific embodiment, the radiolabeled antibody conjugate is administered intravenously or subcutaneously to a subject. In a specific embodiment, the radiolabeled antibody conjugate is administered intratumorally to a subject. Upon administration, the radiolabeled antibody conjugate is localized within the tumor. The localized radiolabeled antibody conjugate is visualized by PET imaging, and the uptake of the radiolabeled antibody conjugate by the tumor is measured by a method known in the art. In a specific embodiment, imaging is performed on day 1, 2, 3, 4, 5, 6, or 7 after the administration of the radiolabeled conjugate. In a specific embodiment, imaging is performed on the day the radiolabeled antibody conjugate is administered.
[0254] In certain embodiments, the radiolabeled anti-MET conjugate may be administered at a dose of about 0.1 mg to about 100 mg per kg of body weight of the subject, for example, about 0.1 mg to about 50 mg per kg of body weight, or about 0.5 mg to about 25 mg, or about 0.1 mg to about 1.0 mg.
[0255] IV. Examples
[0256] Specific embodiments of the present disclosure are illustrated by the following non-limiting embodiments.
[0257] Example 1: Production of human antibodies against MET
[0258] Human anti-MET antibodies comprising those listed in Table 1 were prepared and characterized as described in US-2018-0134794, the entirety of which is incorporated herein by reference. Briefly, human antibodies against MET were generated using an immunogen containing a recombinant human MET extracellular domain fused to human Fc (R&D Systems, Catalog # 358-MT, Minneapolis, MN). The mice used for immunization express a "universal light chain." That is, antibodies produced in these mice have different heavy chain variable regions but essentially the same light chain variable domain.
[0259] Antibody immune responses were monitored using MET-specific immunoassays. Once the desired immune response was achieved, splenocytes were collected and fused with mouse myeloma cells to preserve their viability and form immortal hybridoma cell lines. The hybridoma cell lines were screened and selected to identify those producing MET-specific antibodies. Using these techniques and the aforementioned immunogens, several anti-MET chimeric antibodies (i.e., antibodies possessing a human variable domain and a mouse constant domain) were obtained. Additionally, as described in US Patent No. 2007 / 0280945, several complete human anti-MET antibodies were isolated directly from antigen-positive B cells without fusion with myeloma cells. Exemplary antibodies produced in this manner were designated as H4H13290P2, H4H13291P2, H4H13295P2, H4H13299P2, H4H13300P2, H4H13301P2, H4H13302P2, H4H13306P2, H4H13309P2, H4H13311P2, H4H13312P2, H4H13313P2, H4H13316P2, H4H13318P2, H4H13319P2, H4H13325P2, and H4H13331P2; Table 1 above shows the sequences of these antibodies.
[0260] MET x MET bispecific antibodies were prepared from the anti-MET antibodies of Table 1. All anti-MET antibodies described herein contain the same ("common") light chain (including the light chain variable region [LCVR] amino acid sequence of SEQ ID NO. 138, and the light chain CDR [LCDR1, LCDR2, and LCDR3] amino acid sequences of SEQ ID NOs. 140, 142, and 144). Additionally, all bispecific antibodies exemplified in this example contain a "D2" arm derived from the exemplary anti-MET antibody H4H13312P2. Thus, both antigen-binding domains (D1 and D2) of all bispecific antibodies described in this example contain this common light chain variable region, and all D2 binding arms contain a heavy chain variable region derived from H4H13312P2; however, the bispecific antibodies differ from each other in their D1 heavy chain variable region (HCVR) and heavy chain CDR (HCDR). Exemplary antibodies produced in this manner were designated as H4H14634D, H4H14635D, H4H14636D, H4H14637D, H4H14638D, H4H14639D, H4H14640D, H4H14641D, H4H16445D, H4H16446D, H4H16447D, H4H16448D, and H4H16449D; Table 2 above shows the sequences of these antibodies. For example, the MET x MET bispecific antibody H4H14639D comprises D1-HCVR (Sequence No. 58) from the anti-MET antibody of H4H13306 and D2-HCVR (Sequence No. 82) from the anti-MET antibody of H4H13312P2.
[0261] Example 2: Conjugation of p-SCN-Bn-DFO and MET x MET bispecific antibody H4H14639D
[0262] To modify the parental MET x MET bispecific antibody, H4H14639D, and the isotype control antibody for radiolabeled ImmunoPET studies, the chelator p-SCN-bn-deferoxamine (DFO, also known as desperioxamine; Macrocylics, Catalog #: B-705) was attached to the antibody.
[0263] For the aforementioned modification, 100 mg of 26.1 mg / mL H4H14639D was divided into four aliquots and passed through four pre-equilibrated PD-10 desalting columns (GE Healthcare, Catalog #: 17-0851-01) according to the manufacturer's instructions, with the buffer exchanged with conjugation buffer (150 mM NaCl, 50 mM sodium carbonate, pH 9.0; Sigma-Aldrich, Catalog #: S6297-1KG and Gibco, Catalog #: 24740-011, respectively). The elution products were combined, and the concentration was determined by UV absorption spectroscopy (Thermo Scientific NanoDrop 2000c, Catalog #: ND-2000c-US-CAN) measured at 280 nm and calculated from the primary sequence-based extinction coefficient. These elution products were further diluted with conjugation buffer to 10.4 mg / mL. In a separate vial, p-SCN-Bn-DFO was prepared at a concentration of 13.8 mM in pure dimethyl anhydride (DMSO; Sigma-Aldrich, Catalog #: 276855-100 mL). The p-SCN-Bn-DFO solution was added to the diluted eluent in quarter increments and carefully mixed by pipetting so that the composition of the final reaction solution was 10 mg / mL bispecific antibody in conjugation buffer, 2% DMSO, and a 4-fold molar-to-molar excess of p-SCN-Bn-DFO against the bispecific antibody. This solution was incubated in a 37°C water bath without further stirring. After 30 minutes at 37°C, the reaction solution was divided into four aliquots and rapidly passed through four PD-10 desalting columns pre-equilibrated with a buffer containing 50 mM sodium acetate at pH 5.0 (formulation buffer; Sigma-Aldrich, catalog #32319-1KG-R).The final elution solutions were combined, sterile filtered through a syringe filter (Acrodisc 13 mm syringe filter, Pall Corporation, Catalog #: 4602), and designated as DFO-Ab immunoconjugate, DFO-H4H14639D immunoconjugate.
[0264] Next, concentrations and the DFO-to-antibody ratio (DAR, i.e., chelate-to-antibody ratio) were measured by UV absorption spectroscopy. For absorbance measurements, DFO-conjugated antibodies were measured against formulation buffers at 252 nm (A252), 280 nm (A280), and 600 nm (A600) (see Tables 3 and 4). For calculations, the background at each absorbance value was corrected using the following equation:
[0265]
[0266] Antibody concentration, conjugate concentration, and DAR were calculated using the following formula: MW = 144950 g mol -1 , ε 280 = 207729 M -1 cm -1 , ε 252 = 79048 M -1 cm -1 .
[0267] Antibody concentration calculation
[0268]
[0269] Calculation of conjugate concentration
[0270]
[0271] DAR calculation
[0272]
[0273] The final DFO-Ab immunoconjugate yield was 61 mg.
[0274] For monomer purity, the DFO-Ab immunoconjugate was validated by size exclusion high-performance liquid chromatography (SE-HPLC) using a Superdex 200 Increase 10 / 300 GL column (GE Healthcare, Catalog #: 28990944), with an inline UV absorbance detector monitored at 280 nm and a PBS mobile phase of 0.75 mL / min (see Fig. 1). The major elution peak at approximately 15 min corresponds to the monomeric species. The DFO-Ab immunoconjugate was also evaluated against the unmodified bispecific antibody H4H14639D by dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; Invitrogen, Novex 4-20% Tris-Glycine Mini Gels, Catalog #: XP04200), which was performed according to the manufacturer's instructions (see Fig. 2). The target binding equilibrium constant of the DFO-Ab immune conjugate, i.e., K D It was tested using SPR (GE Healthcare, Biacore 8k), which is the bispecific antibody K D It was determined to be within 10% of.
[0275] DAR, concentration, and monomer purity of the conjugate antibodies DAR Concentration (mg / mL) Monomer (%) H4H14639D 1.26 6.76 99.6%
[0276] Background subtraction UV absorption spectroscopy antibodies A' 280 A' 252 H4H14639D 1.08 0.538
[0277] The bispecific antibody was successfully conjugated to p-SCN-Bn-DFO via a primary amine chemistry reaction, as demonstrated by UV absorption spectroscopy, SE-HPLC, and SDS-PAGE. The calculated DAR of 1.26 was within the expected range of 1.0 to 2.0. The SE-HPLC chromatogram showed a highly monomeric product (99.6%) without detectable low molecular weight species. SDS-PAGE indicated that the bispecific antibody remained unchanged after DFO conjugation.
[0278] Example 3: DFO-conjugated bispecific antibody 89 Zr chelation
[0279] For use in immunoPET in vivo studies, DFO-conjugated MET x MET bispecific antibody, H4H14639D, and DFO-conjugated isomorphic control antibody 89 It was radiolabeled with Zr.
[0280] DFO-conjugated antibody (250 µg) was first prepared in 1 M HEPES, pH 7.4 (Teknova, Catalog #: H1030) to a total volume of 200 μL. Separately, approximately 5 mCi (< 150 μL) 89 The Zr-oxalic acid solution (3D Imaging, Little Rock AR) was neutralized, transferred to a total volume of 1000 μL of 1 M HEPES, pH 7.4, and buffered to pH 6.8 to 7.4. DFO-Ab immunoconjugate and buffered 89 After combining the Zr solutions, they were carefully mixed with a pipette and incubated in a static state at room temperature for 45 minutes. Upon completion, the reaction mixture was rapidly exchanged for buffer using a PD-10 column (GE Healthcare, Catalog #: 17-0851-01) pretreated with 250 mM sodium acetate, pH 5.5 (Sigma-Aldrich, Catalog #: 32319-1KG-R) according to the manufacturer's instructions. The concentration of the elution product, referred to as the DFO-Ab radioimmunoconjugate, was determined by measuring at 280 nm using UV absorption spectroscopy (Thermo Scientific NanoDrop 2000c, Catalog #: ND-2000c-US-CAN) and calculated from the on-DFO-contributed-corrected primary-sequence-based absorption coefficient using the following equation:
[0281]
[0282] DFO-Ab radioimmunoconjugates were sterile filtered and evaluated for protein yield, specific activity (SA), radiochemical purity (RCP), protein purity, and target-specific binding, i.e., immunoreactivity (IR). The data are reported in Table 5. Activity yield (mCi) was measured using a dose calibrator (Capintec CRC-25R; Catalog #: 5130-3215). The protein yield and specific activity of DFO-Ab radioimmunoconjugates were determined using the following equation:
[0283]
[0284] RCP, uncontaminated 89 Zr and protein purity were determined by size exclusion high-performance liquid chromatography (SE-HPLC) using a Superdex 200 Increase 10 / 300 GL column (GE Healthcare, Catalog #: 28990944) equipped with a serially connected inline UV 280 absorbance and gamma emission detector (Agilent Technologies, Model 1260, composed of a Lablogic SCAN-RAM radiodetector) and a PBS mobile phase at a flow rate of 0.75 mL / min. The percentage of protein purity was determined by comparing the relative combined amounts of the high molecular weight (HMW) species peaks (approx. 10 to app. 15 min) and the main peak (approx. 15 to app. 18 min) in the UV 280 chromatogram. Low molecular weight species (approx. 18 to app. 25 min) were not observed. Using a radiochromatogram (gamma emission), unadmixed 89 Radiochemical purity was determined by the relative comparison of the main pig integration for the Zr peak (approx. 25 min) and %HMW species.
[0285] IR of DFO-Ab radioimmunoconjugate in two 500 µL aliquots of EBC-1 cells (JCRB number JCRB0820), A and B ( A : 2.0 x 107 Cells / mL, B : 0.5 x10 7 It was measured by a cell binding assay requiring cells / mL). DFO-Ab radioimmunoconjugate (20 ng) was aliquoted A It was added to and incubated for 45 minutes at 37°C and 5% CO2. Two aliquots A and B All were centrifuged at 1500 rpm for 5 minutes (Eppendorf; Model #5504R). Cell pellet B The supernatant was removed from the cell pellet. A cell pellet B They were transferred to, and then incubated and separated as described above. Each cell pellet ( A and B The sample was washed twice with 1 mL of fresh cell culture medium and centrifuged at 1500 rpm for 5 minutes between each wash. The supernatant was collected from the wash solution. The final activity of all components (each cell pellet resuspended in 500 µL of cell culture medium, the supernatant, and the supernatants of four washes) was measured using a gamma counter (Perkin Elmer Wizard 2; Model #2470-0020). The IR was determined by dividing the sum of the activities of both pellets by the sum of the activities of all components and multiplying the result by 100%. This process was tested on a non-specific DFO-Ab radioimmunoconjugate (n = 1), and the IR was determined to be 2.8%.
[0286] The results of the assay for the DFO-Ab radioimmunoconjugates (n = 5) generated above are recorded in Table 5. In particular, the mean RCP was 94.6 ± 1.2%, and 2.7 ± 1.9% was non-impurity. 89Zr was present, and the protein purity was 98.3 ± 1.5%. Figures 3 and 4 show representative chromatograms, respectively. The SA ranged from 11.9 to 21.3 mCi / mg and was appropriate for in vivo administration. The mean IR was 84 ± 7%, whereas the non-specific control was 2.8%.
[0287] Summary of DFO-Ab Immunoconjugates for In Vivo Imaging and Biodistribution Studies Radioactive Labels / Research # 1 2 3 4 5 Mean ± Standard Deviation Concentration (mg / mL) 0.100 0.103 0.120 0.115 0.120 0.11 ± 0.01 Protein yield (ug) 171 168 203 196 209 189 ± 19 SA(mCi / mg) 16.0 11.9 21.3 12.8 17.2 15.8 ± 3.4 RCP(%) 94.6 92.3 94.8 95.7 95.4 94.6 ± 1.2 Non-marriage 89 Zr 5.4 4.6 1.1 1.4 0.8 2.7 ± 1.9 Protein purity (%) ND 98.2 95.9 99.5 99.5 98.3 ± 1.5 appearance transparency transparency transparency transparency transparency NA IR(%) 91 ND 85 78 86 84 ± 7
[0288] NA: Not applicable ND = Undetermined mAb: H4H14639D
[0289] Example 4: Binding affinity and kinetic constants of MET x MET bispecific antibody and DFO-conjugated MET x MET bispecific antibody
[0290] Equilibrium dissociation constant for hMET.mmh binding to a purified anti-MET x MET bispecific mAb (H4H14639D) or an anti-MET x MET bispecific mAb conjugated to DFO (H4H14639D-DFO) ( K D The value was determined using a real-time surface plasmon resonance biosensor utilizing a Biacore T-200 instrument. The CM5 Biacore sensor surface was derivatized by amine coupling with a monoclonal mouse anti-human Fc antibody to capture purified H4H14639D or H4H14639D-DFO. These Biacore binding studies were performed in a buffer (HBS-P execution buffer) composed of 0.01 M HEPES pH 7.4, 0.15 M NaCl, and 0.05% v / v Surfactant P20. Different concentrations of hMET with a C-terminal myc.myc hexahistidine tag, prepared in HBS-ET execution buffer, were injected onto the antibody capture surface at a flow rate of 50 μL / min. The binding of hMET.mmh to the captured monoclonal antibody was monitored for 5 minutes, and the dissociation of hMET.mmh in HBS-ET run buffer was monitored for 10 minutes. All binding kinetics experiments were performed at 25°C. Dynamic binding ( k a) and Harry( k d The ) rate constant was determined by fitting a real-time sensorgram to a 1:1 coupled model using Scrubber 2.0c curve fitting software. The coupled dissociation equilibrium constant ( K D ) and the dissociation half-life (t½) were calculated from the dynamic rate constant as follows:
[0291]
[0292] Table 6 below shows the binding kinetic parameters of human MET binding to purified antibodies at 25°C.
[0293] Human MET binding kinetics for MET x MET bispecific antibodies and DFO-conjugated MET x MET bispecific antibodies at 25°C Common names Captured mAb (RU) Combined antigen (RU) Antigen concentration (nM) ka (1 / Ms) kd (1 / s) KD (M) t1 / 2 (minute) Chi^2 Theoretical Rmax (RU) Combined % / Theoretical Rmax Unbound isomorphic control group 70.5 ±13.1 0.25 90 NB NB NB NB NB NB NB H4H14639D(non-conjugated) 49.3 ±1.0 26.35 90 3.25E+05 2.72E-03 8.36E-09 4.25 0.469 71.4 36.92 H4H14639D-DFODAR 0.59 49.1 ±0.8 26.68 90 3.02E+05 2.39E-03 7.90E-09 4.84 0.422 71.1 37.54 Unbound isomorphic control group 120.1 ±3.3 -1.46 90 NB NB NB NB NB NB NB H4H14639D-DFODAR 1.02 82.3 ±2.4 46.99 90 2.84E+05 1.83E-03 6.47E-09 6.30 0.656 119.1 39.44 H4H14639D-DFODAR 2.14 83.3 ±1.8 48.39 90 3.69E+05 1.62E-03 4.38E-09 7.14 0.661 120.6 40.13
[0294] Example 5: In vivo biodistribution of radiolabeled MET x MET bispecific antibodies
[0295] Different tumor xenografts were selected for imaging in immunocompromised mice based on MET expression levels: EBC1 (high MET), NCI-H441 (medium MET), and NCI-H358 (low MET). 5 x 10⁶ in SCID mice 6 Dog tumor cells were transplanted and grown for 10 to 14 days. Then, mice were given 0.1 mg / kg 89 Zr-DFO-H4H14639D was administered, and the amount of unlabeled unconjugated antibody was increased to achieve final protein doses of 0.1, 0.5, and 5 mg / kg. To control animals, 0.1 mg / kg of 89 Zr-DFO-isotype control antibodies and unlabeled unconjugated antibodies were administered to achieve a final protein dose of 0.5 mg / kg. PET imaging was performed on days 0, 1, 4, and 6. Biodistribution was performed on day 6.
[0296] PET / CT images were obtained using the Sofie Biosciences G8 PET / CT (Sofie Biosciences and Perkin Elmer). Before obtaining the images 89 The equipment was pre-calibrated for the detection of Zr. The energy window ranged from 150 to 650 keV, and the reconstruction resolution at the center of the field of view was 1.4 mm. Mice were induced anesthetized with isoflurane, and the isoflurane was continuously flowed during imaging. Still images were acquired for 10 minutes using G8 acquisition software and then reconstructed using pre-configured settings. Image data were corrected for attenuation and other parameters. CT images were acquired following PET acquisition and co-registered with the PET images. Images were prepared using VivoQuant post-processing software (inviCRO Imaging Services).
[0297] For biodistribution studies, mice at the final time point ( 89 On day 6 after administration of Zr-DFO-H4H14639D, the patient was euthanized, and blood was collected via cardiac perforation. Tumor and normal tissues were resected and weighed in a counter. Subsequently, the sample was measured on an automated gamma counter (Wizard 2470, Perkin Elmer) during CPM 89 Count data for Zr were collected. The percentage of the injected dose per gram (%ID / g) was calculated for each sample using a standard substance prepared from the injected substance.
[0298] The imaging results 89 It is demonstrated that Zr-DFO-H4H14639D specifically localizes to MET-expressing tumor xenografts (Figs. 5 to 7), which is further confirmed by biodistribution data. 5 mg / kg 89 The blocking doses of Zr-DFO-H4H14639D are 0.1 and 0.5 mg / kg 89Compared to lower doses of Zr-DFO-H4H14639D, NCI-H441 (medium MET) and NCI-H358 (low MET) tumors showed increased blood uptake (% ID / g) and lower tumor uptake (% ID / g) (Fig. 8). In different tumor xenografts 89 The overall tumor uptake of Zr-DFO-H4H14639D demonstrates a good correlation with relative MET expression (Fig. 9).
[0299] Example 6: MET x MET bispecific antibody binding ability (ABC) by saturated radioligand binding assay
[0300] Antibody binding ability (ABC) assays were performed on EBC-1, NCI-H441, and NCI-H358 cell lines 89 Zr-DFO-anti-Met single-arm comparator antibody (Comp1; Onartuzumab, US No. 2016 / 0222115 and Martens et al., Clin Cancer Res 2006, 12(20): 6144-6152) and 89 It was performed using Zr-DFO-H4H14639D as a radioligand. Preparation of radioligand (DFO antibody conjugation and subsequent Zr 89 Examples of radiolabeling have been previously mentioned. All six experiments were performed in a similar manner with the assistance of the Hamilton Starlet liquid handling system. In summary, cells were first harvested and their viability analyzed (confirmed as > 90%) by trypan blue exclusion staining, and 2 to 5 x 10⁶ cells were placed in complete medium. 6 Cells / mL / second were transferred. Next, 100 μL (200,000 to 500,000 cells, N c) was aliquoted along the double or quadruple columns of a V-bottom 96-well plate ("cell plate"). The cell plate was maintained at 4°C until the radiolabeled antibody was administered in a later step. In a second V-bottom 96-well plate ("mAb plate"), 150 μL of radiolabeled antibody (0.10 to 0.12 mg / mL) was aliquoted across the columns of column 1, and a single well in column 12 was aliquoted as an internalization control. Subsequently, columns 2 through 9 were serially diluted 2.8-fold using cold medium. Next, 50 μL of mAb plate was stamped into the cell plate. The cell plate was incubated at 4°C for 45 minutes with careful stirring. After incubation, wells from columns 1 through 9 were first carefully pipette-mixed to create a transient cell suspension; then, 30 μL (or 20% of the total) was drawn from each well and collected in flip-cap tubes containing the administered total antibody. Before removing and discarding the supernatant, the remaining cell plate was spun at 150 g for 5 minutes. Subsequently, the cell plate was washed with 200 μL of cold medium, subjected to 5 aspiration / dispensing cycles before spun again, and the supernatant was removed and discarded. This washing process was repeated two more times before resuspending the cells in 200 μL of cooling buffer (10% FBS in PBS, v / v). Of the 200 μL, 180 μL was drawn from each well and dispensed into flip-cap tubes containing the cell-binding antibody. The activity of the total and bound antibody samples was measured using a gamma counter (Hidex Automatic Gamma Counter, Model #425-601). Based on a dilution series starting from the initial antibody concentration (divided into 5 for sampling), a calibration curve was generated from the total antibody administration samples using the number detected for total antibodies administered per well and total antibodies administered per T. Using the calibration curve, the number of combined fractions (1 due to sampling)(multiplied by 38) was converted into the mass (or concentration) of the bound antibody B.
[0301] Internalization Regulation:
[0302] Additionally, radioligand internalization was analyzed at the highest dose concentration for 45 minutes at 4°C. If significant, ABC was scaled accordingly using the fraction of the internalized antibody. For the internalization control group, the total well content (200 μL) of terminal column 12 was transferred to a 1.5 mL Eppendorf tube containing 1 mL of low pH stripping buffer (50 mM glycine, 150 mM NaCl, pH 2.4) and incubated at room temperature for 10 minutes. After incubation for 10 minutes, the Eppendorf tube was spun at 150 g for 5 minutes. The supernatant was removed without disturbing the cell pellet and preserved for counting. The cell pellet was washed 10 times with 1 mL of cold buffer (10% FBS in PBS, v / v), and aspiration, spun, removal, and preservation were performed between washes. The activity of the cell pellet, supernatant, and wash supernatant was measured using a gamma counter. The internalized fraction, I, was calculated as the ratio of the activity of the cell pellet to the sum of the total activities of the cell pellet, stripping supernatant, and wash supernatant.
[0303] ABC of Comp1:
[0304] Assuming the law of mass action under single-site conditions, binding saturation data were fitted using Equation 1. Binding values were determined and converted to ABC via Equation 2. According to the binding / washing protocol, non-specific binding was determined to be a negligible component in all runs and was not considered as part of the analysis. Internalization was determined to make a negligible contribution to the bound radioactivity and was also not considered as part of the analysis.
[0305] Equation 1 (for Comp1):
[0306]
[0307] During the meal, K D is the equilibrium dissociation constant (nM) (fitting parameter), and T Ag is the total Ag(nM) (fitting parameter), T is the total antibody administered (nM) (measurement), and B is the binding concentration (nM) (measurement).
[0308] Equation 2:
[0309]
[0310] During the meal, N A ε is Avogadro's number, V is the well volume (150 μL), and N c is the number of cells per well (known).
[0311] ABC of H4H14639D:
[0312] Since there are multiple binding formats for H4H14639D, the dataset was fitted using the Hill-Langmuir equation (Equation 3). Subsequently, ABC was calculated using Equation 2. Non-specific binding was determined to be a negligible component in all runs and was not considered part of the analysis. Radioligand internalization was determined to make a non-negligible contribution to the bound radioactivity measurements and was compensated accordingly.
[0313] Equation 3 (for H4H14639D):
[0314]
[0315] Among the foods, B and T Ag is as previously stated, I is the internalized fraction (measurement), and K l , n and T Ag is a fitting parameter.
[0316] The ABC results are summarized in Tables 7 and 8 and illustrated in Figures 10a and 10b.
[0317] ABC of Comp1 for 3 cell lines tested using Equations 1 and 2. The internalized fraction at 4℃ was negligible. ABC / Cell line EBC-1 NCI-H441 NCI-H358 Mean ± Standard Deviation x 10 3 , n 250 ± 10, 4 62 ± 3, 4 21 ± 4, 2
[0318] ABC of H4H14639D for 3 cell lines tested using Equations 2 and 3. ABC / Cell line EBC-1 NCI-H441 NCI-H358 Mean ± Standard Deviation x 10 3 , n 310 ± 30, 4 46.25 ± 0.01, 2 37 ± 4, 2 Fraction internalized under experimental conditions (4℃) 0.237 0.172 0.09
[0319] The ABC value obtained using Comp1, an anti-Met, single-arm / single-valent format antibody, is a reasonable estimate of the Met receptor copy number (i.e., a 1:1 antibody against the receptor). However, the ABC value obtained using antibody H4H14639D is not expected to a priori represent a 1:1 Met receptor copy number.
[0320] The foregoing embodiments and examples are intended merely to be exemplary and non-limiting. Those skilled in the art will recognize or be convinced of numerous equivalents of specific compounds, materials, and methods through experiments not exceeding the ordinary scope. All such equivalents are deemed to be within the scope of the invention and are included in the appended claims.
Claims
Claim 1 A radiolabeled antibody conjugate comprising an antibody that binds to MET or its antigen-binding fragment, a chelating moiety, and a positron emitter, wherein the antibody or its antigen-binding fragment comprises (i) three heavy chain complementarity determining regions (HCDR) within a heavy chain variable region (HCVR); and (ii) three light chain complementarity determining regions (LCDR) within a light chain variable region (LCVR), wherein the HCVR has an amino acid sequence consisting of SEQ ID NO. 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, or 130, and the LCVR has the amino acid sequence of SEQ ID NO.
138. Claim 2 In paragraph 1, the antibody or its antigen-binding fragment is of the chemical formula ( A Radiolabeled antibody conjugate covalently bonded to one or more moieties of ):-LM Z Chemical formula ( A )(wherein L is a chelation moiety; M is a positron emitter; z is independently 0 or 1 in each case; and at least one of z is 1). Claim 3 In claim 1, the chelating moiety is a radiolabeled antibody conjugate comprising desperioxamine. Claim 4 In paragraph 1, the positron emitter 89 Zr-labeled radiolabeled antibody conjugate. Claim 5 In Paragraph 2, -LM is, And, in the equation, Zr is a positron emitter 89 Zr-labeled radiolabeled antibody conjugate. Claim 6 In paragraph 2, the antibody or its antigen-binding fragment is of the chemical formula ( A A radiolabeled antibody conjugate covalently bonded to one, two, or three moiety of ). Claim 7 In claim 1, the antibody or its antigen-binding fragment has the property of being a multispecific antigen-binding molecule comprising (i) a first binding specificity to MET and a second binding specificity to cancer-specific antigens; (ii) a multispecific antigen-binding molecule comprising a first binding specificity to one epitope of MET and a second binding specificity to a second epitope of MET; (iii) an equilibrium dissociation constant (K) of less than 230 nM when measured by surface plasmon resonance at 25°C or 37°C. D (iv) property of binding to monomeric human MET; (iv) equilibrium dissociation constant (K) less than 3 nM when measured by surface plasmon resonance at 25°C or 37°C D A radiolabeled antibody conjugate having one or more properties selected from the group consisting of: (v) a property of binding to dimeric human MET; (vi) a property of blocking the binding of HGF to MET; and (vi) a property of inhibiting cancer growth in a subject with cancer and extending the survival period of a subject with cancer. Claim 8 In claim 1, the antibody or its antigen-binding fragment is a radiolabeled antibody conjugate comprising three CDRs within the HCVR of SEQ ID NO.
18. Claim 9 In claim 1, the antibody or its antigen-binding fragment is a radiolabeled antibody conjugate comprising three CDRs within HCVR of SEQ ID NO.
58. Claim 10 In claim 1, the antibody or its antigen-binding fragment is a radiolabeled antibody conjugate comprising three CDRs within the HCVR of SEQ ID NO.
82. Claim 11 In claim 1, the antibody or its antigen-binding fragment is a radiolabeled antibody conjugate comprising three CDRs within the LCVR of SEQ ID NO.
138. Claim 12 In claim 1, the antibody or its antigen-binding fragment comprises: (i) an HCDR1 domain having an amino acid sequence consisting of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, or 132; (ii) an HCDR2 domain having an amino acid sequence consisting of SEQ ID NOs 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, or 134; (iii) SEQ ID NOs 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, A radiolabeled antibody conjugate comprising: (iv) an LCDR1 domain having an amino acid sequence of 96, 104, 112, 120, 128, or 136; (v) an LCDR2 domain having an amino acid sequence of SEQ ID NO. 140; and (vi) an LCDR3 domain having an amino acid sequence of SEQ ID NO.
144. Claim 13 In claim 12, the antibody or its antigen-binding fragment comprises a radiolabeled antibody conjugate comprising HCDR1 presented in SEQ ID NO. 20, HCDR2 presented in SEQ ID NO. 22, and HCDR3 presented in SEQ ID NO.
24. Claim 14 In claim 12, the antibody or its antigen-binding fragment comprises a radiolabeled antibody conjugate comprising HCDR1 presented in SEQ ID NO. 60, HCDR2 presented in SEQ ID NO. 62, and HCDR3 presented in SEQ ID NO.
64. Claim 15 In claim 12, the antibody or its antigen-binding fragment comprises a radiolabeled antibody conjugate comprising HCDR1 presented in SEQ ID NO. 84, HCDR2 presented in SEQ ID NO. 86, and HCDR3 presented in SEQ ID NO.
88. Claim 16 A radiolabeled antibody conjugate according to claim 1, wherein the antibody or its antigen-binding fragment comprises (i) a first antigen-binding domain (D1); and (ii) a second antigen-binding domain (D2), wherein D1 specifically binds to a first epitope of human MET; and D2 specifically binds to a second epitope of human MET. Claim 17 In claim 16, a radiolabeled antibody conjugate comprising: (i) D1 containing a CDR within the HCVR amino acid sequence of SEQ ID NO. 58; and (ii) D2 containing a CDR within the HCVR amino acid sequence of SEQ ID NO.
82. Claim 18 In claim 16, (i) D1 comprises HCDR1 presented in SEQ ID NO. 60, HCDR2 presented in SEQ ID NO. 62, HCDR3 presented in SEQ ID NO. 64, LCDR1 presented in SEQ ID NO. 140, LCDR2 presented in SEQ ID NO. 142, and LCDR3 presented in SEQ ID NO. 144; and (ii) D2 comprises HCDR1 presented in SEQ ID NO. 84, HCDR2 presented in SEQ ID NO. 86, HCDR3 presented in SEQ ID NO. 88, LCDR1 presented in SEQ ID NO. 140, LCDR2 presented in SEQ ID NO. 142, and LCDR3 presented in SEQ ID NO. 144, a radiolabeled antibody conjugate. Claim 19 A pharmaceutical composition comprising a radiolabeled antibody conjugate of any one of claims 1 to 18 for use in imaging the localization of a radiolabeled antibody conjugate in tissues expressing MET and visualizing MET expression by positron emission tomography (PET) imaging. Claim 20 A pharmaceutical composition comprising a radiolabeled antibody conjugate of any one of claims 1 to 18 for use in identifying MET-expressing cancer in a subject, comprising the steps of: administering the composition to a subject; and imaging the radiolabeled antibody conjugate through positron emission tomography (PET), wherein the localization of the radiolabeled antibody conjugate in the subject indicates MET-expressing cancer. Claim 21 A pharmaceutical composition comprising a radiolabeled antibody conjugate of any one of claims 1 to 18 for use in a method for treating a subject having cancer, wherein the method comprises: (a) determining that the cancer is MET-positive by administering the composition to a subject; and imaging the localization of the radiolabeled antibody conjugate in the cancer by positron emission tomography (PET) imaging, wherein the presence of the radiolabeled antibody conjugate in the cancer indicates that the cancer is MET-positive; and (b) using one or more doses of an inhibitor of the HGF / MET signaling pathway to treat the subject. Claim 22 A pharmaceutical composition according to claim 21, wherein 0.1 to 10 mg / kg of a radiolabeled antibody conjugate is administered to a subject. Claim 23 In paragraph 21, a pharmaceutical composition wherein the radiolabeled antibody conjugate is administered subcutaneously or intravenously to a subject. Claim 24 A pharmaceutical composition according to claim 21, wherein PET imaging is performed on days 2 to 7 after administration of a radiolabeled antibody conjugate. Claim 25 In paragraph 21, step (a) is a pharmaceutical composition performed prior to step (b). Claim 26 A pharmaceutical composition according to claim 21, wherein the method further comprises: (a) administering a radiolabeled antibody conjugate after treating a subject with at least one dose of an inhibitor of the HGF / MET signaling pathway; and (b) imaging the localization of the radiolabeled antibody conjugate in cancer by PET imaging, wherein a decrease in the localized area of the radiolabeled antibody conjugate in cancer relative to baseline indicates cancer regression. Claim 27 A pharmaceutical composition according to claim 21, wherein a radiolabeled antibody conjugate is administered to a subject at week 1 to 20 after administration of an inhibitor of the HGF / MET signaling pathway. Claim 28 A pharmaceutical composition according to claim 21, wherein the cancer is selected from the group consisting of astrocytoma, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, glioblastoma, head and neck cancer, Kaposi sarcoma, kidney cancer, leiomyosarcoma, liver cancer, lung cancer, malignant glioma, malignant mesothelioma, melanoma, mesothelioma, malignant fibrous histiocytoma, fibrosarcoma, nasopharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, synovial sarcoma, thyroid cancer, and Wilms tumor. Claim 29 A pharmaceutical composition in which, in paragraph 28, the head and neck cancer is a head and neck squamous cell carcinoma. Claim 30 A pharmaceutical composition according to claim 21, wherein the cancer is selected from the group consisting of gastric cancer or non-small cell lung cancer. Claim 31 A pharmaceutical composition in which, in paragraph 30, gastric cancer is gastric cancer with MET amplification. Claim 32 A pharmaceutical composition in which, in paragraph 28, the lung cancer is non-small cell lung cancer. Claim 33 A pharmaceutical composition according to claim 21, wherein the inhibitor of the HGF / MET signaling pathway is an antibody or an antigen-binding fragment thereof. Claim 34 A pharmaceutical composition according to claim 21, wherein the inhibitor of the HGF / MET signaling pathway is a MET x MET bispecific antibody or an antigen-binding fragment thereof. Claim 35 A pharmaceutical composition according to claim 34, wherein the MET x MET bispecific antibody or the antigen-binding fragment thereof comprises (i) a first antigen-binding domain (D1) comprising a CDR within the HCVR amino acid sequence of SEQ ID NO. 58; and (ii) a second antigen-binding domain (D2) comprising a CDR within the HCVR amino acid sequence of SEQ ID NO.
82. Claim 36 A pharmaceutical composition according to claim 35, wherein the MET x MET bispecific antibody or its antigen-binding fragment comprises a CDR within the LCVR amino acid sequence of SEQ ID NO.
138. Claim 37 A pharmaceutical composition according to claim 35, wherein (i) D1 comprises HCDR1 presented in SEQ ID NO. 60, HCDR2 presented in SEQ ID NO. 62, HCDR3 presented in SEQ ID NO. 64, LCDR1 presented in SEQ ID NO. 140, LCDR2 presented in SEQ ID NO. 142, and LCDR3 presented in SEQ ID NO. 144; and (ii) D2 comprises HCDR1 presented in SEQ ID NO. 84, HCDR2 presented in SEQ ID NO. 86, HCDR3 presented in SEQ ID NO. 88, LCDR1 presented in SEQ ID NO. 140, LCDR2 presented in SEQ ID NO. 142, and LCDR3 presented in SEQ ID NO.
144. Claim 38 A pharmaceutical composition according to claim 35, wherein D1 comprises the heavy chain variable region (HCVR) of SEQ ID NO. 58; and D2 comprises the HCVR of SEQ ID NO.
82. Claim 39 Compound of chemical formula (III): A compound wherein A is an antibody that binds to MET or an antigen-binding fragment thereof, and k is an integer from 1 to 30, and the antibody or the antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR) within a heavy chain variable region (HCVR); and three light chain complementarity determining regions (LCDR) within a light chain variable region (LCVR), wherein the HCVR has an amino acid sequence consisting of SEQ ID NO. 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, or 130, and the LCVR has the amino acid sequence of SEQ ID NO.
138. Claim 40 In paragraph 39, k is a compound of 1 or 2. Claim 41 In claim 39, the antibody or its antigen-binding fragment comprises: (i) an HCDR1 domain having an amino acid sequence consisting of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, or 132; (ii) an HCDR2 domain having an amino acid sequence consisting of SEQ ID NOs 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, or 134; (iii) SEQ ID NOs 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, A compound comprising: (iv) an LCDR1 domain having an amino acid sequence of 88, 96, 104, 112, 120, 128, or 136; (v) an LCDR2 domain having an amino acid sequence of SEQ ID NO. 140; (vi) an LCDR3 domain having an amino acid sequence of SEQ ID NO. 142; and (vi) an LCDR3 domain having an amino acid sequence of SEQ ID NO.
144. Claim 42 (i) an antibody or its antigen-binding fragment that binds to MET and (ii) an antibody conjugate comprising one or more chelating moieties, wherein the antibody or its antigen-binding fragment comprises three heavy chain complementarity determining regions (HCDR) within a heavy chain variable region (HCVR); and three light chain complementarity determining regions (LCDR) within a light chain variable region (LCVR), wherein the HCVR has an amino acid sequence consisting of SEQ ID NO. 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, or 130, and the LCVR has the amino acid sequence of SEQ ID NO.
138. Claim 43 In paragraph 42, the chelating moiety is, is, and among the food An antibody conjugate that is a covalent bond to an antibody or its antigen-binding fragment. Claim 44 In paragraph 42, the conjugate is an antibody conjugate having a chelation moiety-to-antibody ratio of 1.0 to 3.
0. Claim 45 In paragraph 42, the antibody conjugate has a chelation moiety-to-antibody ratio of 1.
3. Claim 46 In any one of claims 42 to 45, the antibody or its antigen-binding fragment comprises: (i) an HCDR1 domain having an amino acid sequence consisting of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 108, 116, 124, or 132; (ii) an HCDR2 domain having an amino acid sequence consisting of SEQ ID NOs 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 94, 102, 110, 118, 126, or 134; (iii) SEQ ID NOs 8, 16, 24, 32, 40, 48, 56, 64, An antibody conjugate comprising: (iv) an LCDR1 domain having an amino acid sequence of 72, 80, 88, 96, 104, 112, 120, 128, or 136; (v) an LCDR2 domain having an amino acid sequence of SEQ ID NO. 140; and (vi) an LCDR3 domain having an amino acid sequence of SEQ ID NO.
144. Claim 47 (i) an antibody that binds to MET or its antigen-binding fragment, desperioxamine, and 89 A radiolabeled antibody conjugate comprising a Zr positron emitter, wherein the antibody or its antigen-binding fragment comprises (a) at least one HCVR having an amino acid sequence consisting of SEQ ID NO. 58, 2, 10, 18, 26, 34, 42, 50, 66, 74, 82, 90, 98, 106, 114, 122, or 130; and (b) at least one LCVR having the amino acid sequence of SEQ ID NO. 138; and (ii) a composition comprising a MET-expressing cancer cell. Claim 48 A radiolabeled antibody conjugate comprising a multiplex specific antigen-binding molecule that binds to MET, a chelating moiety, and a positron emitter, wherein the multiplex specific antigen-binding molecule comprises (a) three heavy chain complementarity determining regions (HCDR) within a heavy chain variable region (HCVR); and (b) three light chain complementarity determining regions (LCDR) within a light chain variable region (LCVR), wherein the HCVR has an amino acid sequence consisting of SEQ ID NO. 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, or 130, and the LCVR has the amino acid sequence of SEQ ID NO.
138. Claim 49 In claim 48, the multispecific antigen-binding molecule comprises (i) a first antigen-binding domain (D1); and (ii) a second antigen-binding domain (D2), wherein D1 specifically binds to a first epitope of human MET; D2 specifically binds to a second epitope of human MET; D1 comprises a CDR within the HCVR amino acid sequence of SEQ ID NO. 58; and D2 comprises a CDR within the HCVR amino acid sequence of SEQ ID NO. 82, a radiolabeled antibody conjugate.
Citation Information
Patent Citations
ANTI-Met MONOCLONAL ANTIBODY FOR USE IN TUMOR DIAGNOSIS, FRAGMENT AND DERIVATIVE THEREOF, AND CORRESPONDING COMPOSITION AND KIT
JP2009292815A
Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
US20090297439A1
Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
WO2018093866A1
